On this page
Quick Reference
Overview and Recommendations
Background
- •Recognize malaria as a major global health threat, with approximately 250 million cases and over 600,000 deaths annually, disproportionately affecting children under five and pregnant women in sub-Saharan Africa.
- •Identify the five primary human pathogens: (most virulent), P. vivax (common in Asia/Americas, forms dormant liver stages), P. ovale (also forms liver stages), P. malariae (72-hour cycle), and P. knowlesi (zoonotic, 24-hour cycle).
- •Understand the life cycle involving the female mosquito vector, which injects sporozoites that first infect the liver (exo-erythrocytic cycle) before entering the bloodstream to infect red blood cells (erythrocytic cycle).
- •Note the emergence of artemisinin partial resistance (ART-R), particularly in Southeast Asia and parts of Africa, characterized by delayed parasite clearance and mutations in the pfk13 gene.
- •Consider host genetic factors that influence disease course, such as (risk of hemolysis with certain drugs), the Duffy-negative phenotype (historically protective against P. vivax), and sickle cell trait (protective against severe P. falciparum).
Evaluation
- •Suspect malaria in any patient with an unexplained fever who has lived in or traveled to an endemic region within the last year, even if they took chemoprophylaxis.
- •Ask about the pattern of fever paroxysms (chills, high fever, and sweating), though classic 48- or 72-hour cycles are often absent in the early stages or in non-immune individuals.
- •Examine for signs of severe disease, including altered mental status (cerebral malaria), respiratory distress (acidotic breathing), jaundice, and spontaneous bleeding or petechiae.
- •Order immediate parasitological testing with thick and thin blood smears; the thick smear is used for screening (sensitivity 50–100 parasites/µL), while the thin smear is used for species identification and quantification.
- •Utilize Rapid Diagnostic Tests (RDTs) for Histidine-Rich Protein 2 (HRP2) or parasite Lactate Dehydrogenase (pLDH) when microscopy is unavailable, but be aware of false negatives in HRP2-deleted strains.
- •Repeat blood smears every 6–12 hours for 48 hours if the initial test is negative but clinical suspicion remains high, as parasitemia can fluctuate significantly.
- •Screen for red flags of severe malaria: Glasgow Coma Scale (GCS) < 11, hemoglobin < 7 g/dL, serum creatinine > 3 mg/dL, or blood glucose < 40 mg/dL.
- •Perform pulse oximetry on all patients; an SpO2 < 90% is a high-risk marker for mortality and indicates the need for urgent respiratory support.
- •Evaluate for (CM) by assessing consciousness using the Blantyre Coma Scale in children or GCS in adults; CM is defined by a GCS < 11 persisting for >1 hour after a seizure.
- •Obtain a complete blood count (CBC) to assess for thrombocytopenia and anemia, and a metabolic panel to monitor for acute kidney injury (MAKI) and hypoglycemia.
- •Rule out other tropical febrile illnesses such as , , and , which often present with overlapping symptoms.
- •Test for using a point-of-care biosensor before initiating radical cure therapy for P. vivax or P. ovale to prevent life-threatening hemolysis.
Management
- •Administer intravenous (IV) 2.4 mg/kg at 0, 12, and 24 hours for all cases of severe malaria, regardless of the infecting species.
- •Transition to a full 3-day course of oral Artemisinin-based Combination Therapy (ACT) once the patient with severe malaria can tolerate oral intake.
- •Treat uncomplicated P. falciparum with oral Artemether-lumefantrine (20/120 mg tablets, weight-based dosing twice daily for 3 days) as the first-line regimen.
- •Use Dihydroartemisinin-piperaquine as an alternative ACT in regions with documented resistance to artemether-lumefantrine.
- •Provide radical cure for P. vivax and P. ovale by administering Primaquine 0.25–0.5 mg/kg daily for 14 days to eliminate latent liver hypnozoites.
- •Ensure G6PD activity is >30% before giving primaquine; in patients with intermediate deficiency (30-70% activity), consider weekly primaquine (0.75 mg/kg) for 8 weeks under close supervision.
- •Manage hypoglycemia aggressively with IV Dextrose (e.g., 10% dextrose 5 mL/kg in children) and monitor blood glucose every 4 hours, as quinine and the infection itself can cause profound drops.
- •Control seizures with IV Diazepam 0.3 mg/kg or Midazolam 0.1 mg/kg; if seizures recur, escalate to Phenobarbital 20 mg/kg IV.
- •Maintain fluid homeostasis using balanced crystalloids (Lactated Ringer's) at 3-4 mL/kg/hr, but avoid aggressive fluid boluses in cerebral malaria unless the patient is in shock to prevent cerebral edema.
- •Monitor for delayed post-artesunate hemolysis (PADH), which can occur 1–3 weeks after treatment with IV artesunate, particularly in patients with high initial parasitemia.
- •Avoid using artemisinin monotherapy, as this rapidly drives the development of drug resistance.
- •Refer all pregnant women with malaria for specialist obstetric and infectious disease consultation, as they are at high risk for severe anemia and placental sequestration.
- •Implement Seasonal Malaria Chemoprevention (SMC) with sulfadoxine-pyrimethamine plus amodiaquine (SPAQ) in children aged 3–59 months in high-transmission seasonal areas.
- •Recommend the R21/Matrix-M or RTS,S/AS01 vaccine for children in endemic regions as part of a multi-tiered prevention strategy.
- •Discharge patients only after they have completed at least 24 hours of oral therapy, are afebrile, have a declining parasite count, and can tolerate oral medications and fluids.
Board Review — High Yield
- •Cerebral malaria — Defined by GCS < 11 or Blantyre ≤ 2 in the presence of P. falciparum parasitemia.
- •Blackwater fever — Severe intravascular hemolysis leading to hemoglobinuria (dark urine), often associated with P. falciparum.
- •Schüffner dots — Fine stippling seen in red blood cells infected with P. vivax or P. ovale.
- •Banana-shaped gametocytes — Pathognomonic microscopic finding for P. falciparum.
- •Hypnozoites — Dormant liver stages of P. vivax and P. ovale responsible for clinical relapses months later.
- •Maurer clefts — Membranous sacs seen in P. falciparum-infected erythrocytes used for protein transport.
- •Duffy Antigen — The receptor required for P. vivax entry; Duffy-negative individuals (common in West Africa) are largely resistant.
- •Sequestration — P. falciparum cytoadherence to vascular endothelium via PfEMP1, causing microvascular obstruction.
- •Recrudescence — Reappearance of parasitemia from the blood cycle (due to treatment failure), distinct from relapse (from liver).
Deep Dive — Evidence Details
Definition, Synonyms, and Classification of Malaria
- ▸Malaria is caused by Apicomplexan parasites of the genus Plasmodium, transmitted by Anopheles mosquitoes [1, 3].
- ▸Five main species infect humans: P. falciparum, P. vivax, P. ovale, P. malariae, and the zoonotic P. knowlesi [2, 7, 16].
- ▸Clinical classification distinguishes between uncomplicated malaria and severe malaria, the latter involving organ dysfunction such as cerebral malaria [6].
Malaria is an acute and potentially life-threatening febrile illness caused by obligate intracellular protozoan parasites of the genus , which are transmitted to humans through the bites of infected female mosquitoes [1]D[3]D[10]D. These parasites belong to the phylum Apicomplexa, a diverse group of microbes that evolved from phototrophic ancestors to become specialized symbionts [1]D. In humans, the disease is characterized by periodic paroxysms of chills, fever, and sweating, often accompanied by anemia and splenomegaly [18]D. While primarily a human disease, various species infect a wide range of hosts, including non-human primates, birds, and reptiles [11]D[12]D[20]D.
Synonyms and Alternate Names
Historically and across different clinical contexts, malaria has been referred to by several names:
- Ague: An archaic term for the shivering fits or malarial chill.
- Marsh Fever: A historical name reflecting the association between stagnant water (mosquito breeding sites) and disease transmission.
- Quartan Malaria: Specifically refers to the 72-hour cycle of fever paroxysms characteristic of P. malariae [2]D.
- Tertian Malaria: Refers to the 48-hour cycle of fever seen in P. falciparum, P. vivax, and P. ovale.
- Paludism: Derived from the Latin palus (marsh), commonly used in French and Spanish medical literature.
- Zoonotic Malaria: Specifically refers to infections transmitted from animals to humans, most notably P. knowlesi [7]D.
Clinical Phases and Definitions
To standardize the description of malaria's clinical course, the following terms are utilized to define the stages of infection and recovery:
- Prodromal Phase: The initial period following the incubation period (which varies by species) where the patient experiences non-specific symptoms such as headache, malaise, and myalgia before the onset of classic paroxysms [18]D.
- Progressive Phase: The stage characterized by an increasing parasite burden in the blood (erythrocytic cycle), leading to escalating clinical severity and the potential development of complications such as severe anemia or organ dysfunction [9]D.
- Nadir: In the context of malaria, this typically refers to the lowest point of hematologic parameters, particularly hemoglobin levels or platelet counts, which often occurs during or immediately after the peak of parasitemia.
- Plateau: A period where the clinical symptoms and parasite density stabilize, often seen in semi-immune individuals or during the early stages of effective treatment.
- Recovery Phase: The period following the clearance of parasites from the peripheral blood, characterized by the resolution of symptoms and the restoration of normal physiologic function.
- Nadir of Parasitemia: The point at which parasites are no longer detectable by microscopy or PCR following successful intervention [19]D.
Classification of Plasmodium Species
Human malaria is caused by five primary species of the genus . Classification is based on morphological characteristics, the length of the erythrocytic cycle, and clinical virulence. Recent genomic evidence has also identified specific adaptations, such as the ability of P. vivax to infect Duffy-negative individuals in sub-Saharan Africa, a population previously thought to be resistant [16]D.
Classification by Clinical Severity
Malaria is clinically categorized into two major forms to guide protocols:
- Uncomplicated Malaria: Symptomatic infection with a low parasite density and no evidence of vital organ dysfunction. Symptoms often overlap with other tropical febrile illnesses like Zika or Oropouche virus [15]D[18]D.
- Severe Malaria: Defined by the presence of one or more of the following: cerebral malaria (characterized by CXCL10high microglia driving neuroinflammation [6]D), severe anemia, acute kidney injury, or pulmonary edema.
Vector Classification
Transmission is dependent on mosquitoes of the genus. These are often classified into species complexes, which are groups of morphologically identical but genetically distinct cryptic species [3]D[5]D. For example, the Anopheles cruzii complex in the Brazilian Atlantic Forest consists of at least five cryptic species (A-E) [3]D. Identifying these complexes is critical because different members may have varying host-seeking behaviors, such as a preference for human versus animal hosts [14]D.
| Species | Common Name | Erythrocytic Cycle | Key Distinguishing Features |
|---|---|---|---|
| P. falciparum | Malignant tertian | 48 hours | Highest virulence; responsible for most deaths; associated with k13 mutations and artemisinin resistance [9]D[19]D. |
| P. vivax | Benign tertian | 48 hours | Forms hypnozoites (latent liver stage); increasingly found in Duffy-negative African populations [16]D. |
| P. malariae | Quartan malaria | 72 hours | Longest cycle; generally lower parasitemia and milder symptoms [2]D. |
| P. ovale | Ovale tertian | 48 hours | Similar to P. vivax; also forms hypnozoites; primarily found in sub-Saharan Africa. |
| P. knowlesi | Zoonotic malaria | 24 hours | Primarily infects long-tailed macaques; can cause severe disease in humans due to rapid 24-hour cycle [7]D. |
Epidemiology and Risk Factors
- ▸Malaria risk is geographically heterogeneous and depends on ecological, vector, behavioural, healthcare-access, and intervention-related factors [201][205][218][219].
- ▸Infants and young children, including children younger than 5 years and potentially those younger than 10 years in seasonal-transmission settings, are key target populations for malaria prevention [202][203][204][206].
- ▸Cattle may either divert vectors from humans or increase transmission through zoopotentiation; neighbourhood-level livestock distribution is relevant [205].
- ▸Malaria and anaemia overlap substantially in young children, but anaemia studies should not automatically be interpreted as malaria-specific epidemiology [217][220].
- ▸Delayed diagnosis, treatment, and adherence are modifiable behavioural and health-system determinants of malaria outcomes [218].
- ▸Antimalarial resistance-associated kelch13 mutations remain an important population-level surveillance concern despite generally high ACT efficacy in the reviewed studies [209].
Global and geographical epidemiology
Malaria transmission remains spatially heterogeneous, with substantial variation between and within countries according to ecological conditions, vector abundance, human exposure, access to prevention and care, and the intensity of control programmes [201][205][219]. Recent evidence spans high-burden settings in sub-Saharan Africa, including Mali, Sierra Leone, Malawi, Burkina Faso, Uganda, Nigeria, Côte d’Ivoire, Ghana, the Democratic Republic of the Congo, and South Africa, as well as persistent transmission in parts of Indonesia [202][203][204][206][214][217][218]C[219][220]. East Sumba, Indonesia, was specifically characterised by marked differences in malaria incidence between locations, and household survey sampling incorporated both urban and rural areas and communities with high and low incidence [219].
Flooding and environmental disruption may alter infectious-disease patterns and surveillance needs. Following the September 2023 dam collapse and catastrophic flooding in eastern Libya, routine surveillance reports documented temporal and geographical variation in infectious diseases through December 2023; the available study concerned post-flood communicable-disease surveillance rather than a malaria-specific causal analysis [212]. Accordingly, flood-related changes should be regarded as a potential contextual risk requiring surveillance rather than as a quantified malaria risk estimate from this study [212].
Age and pregnancy
Young children are a major epidemiological risk group. Recent studies evaluated malaria and malaria-related outcomes in infants aged 4–11 months, infants enrolled at 6–10 weeks, children aged 6 months, children younger than 5 years, and children younger than 10 years [202][203][204][206]. In Burkina Faso, seasonal malaria chemoprevention (SMC) was studied in children younger than 5 years and in an extended group younger than 10 years, reflecting concern that clinically important transmission and parasite or gametocyte carriage also occur beyond the conventional under-five target age [206]. In Malawi, an efficacy and safety trial combined malaria chemoprevention with iron or multiple-micronutrient powder supplementation in rural children enrolled at 6 months, because malaria-endemic settings commonly overlap with childhood anaemia risk [204].
Pregnancy is an important epidemiological context for malaria prevention and for evaluation of antimalarial mass-drug-administration programmes. The available pregnancy-specific evidence in these references concerns inadvertent periconception exposure to ivermectin during cluster-randomised trials in Mozambique and Kenya, rather than malaria infection risk itself [207]. The trials assessed three monthly rounds of ivermectin at 400 μg/kg against placebo, and the pregnancy analysis addressed adverse pregnancy outcomes after exposure around conception [207].
Environmental and vector-related risk factors
Livestock ownership and the spatial distribution of cattle may modify malaria risk through competing ecological mechanisms. Zooprophylaxis describes diversion of mosquito blood-feeding from humans to livestock, which could reduce transmission; zoopotentiation describes the alternative possibility that livestock increase vector abundance or otherwise enhance transmission [205]. A spatial analysis from a cluster-randomised trial examined cattle around households and incorporated animals owned by neighbours, addressing the limitation of treating livestock only as a household asset [205]. The evidence therefore supports considering the broader neighbourhood distribution of cattle when studying malaria risk, but it does not establish a uniform protective or harmful effect in all settings [205].
Indoor residual spraying (IRS) with pyrethroid insecticides is a malaria-control intervention that can produce substantial population exposure to these chemicals [214]. In the Venda Health Examination of Mothers, Babies and their Environment study, maternal urinary concentrations of four pyrethroid metabolites were measured around pregnancy, and repeated infection-related symptoms were assessed in early school-aged children using shorter recall periods than in some earlier work [214]. The study was designed to investigate whether prenatal pyrethroid exposure was associated with childhood infection symptoms; it should not be interpreted as evidence that IRS itself increases malaria incidence [214].
Host, nutritional, and comorbidity-related factors
Malaria and anaemia are closely linked public-health problems among children younger than 5 years in sub-Saharan Africa [217]. A propensity-score-matched analysis of the 2018–2019 Uganda Malaria Indicator Survey was undertaken to estimate the causal effect of malaria infection on anaemia while accounting for socioeconomic and demographic confounding [217]. This design addresses confounding more directly than conventional cross-sectional regression, although the underlying survey remains observational and cross-sectional [217]. The DRC’s 2023–2024 Demographic and Health Survey included 11,393 children aged 6–59 months in an analysis of anaemia prevalence, spatial clustering, and individual- and community-level determinants; the study assessed anaemia rather than malaria directly, so its geographic findings are relevant as overlapping vulnerability indicators rather than as malaria-specific risk estimates [220].
Coinfection may complicate malaria epidemiology and clinical presentation. An umbrella review identified 21 systematic reviews of malaria coinfections published between 2000 and March 2026 and synthesised prevalence and epidemiological patterns across concurrent infections [211]. The review assessed risk of bias, certainty of evidence, and overlap among primary studies, indicating that reported coinfection prevalence should be interpreted in light of heterogeneous underlying evidence [211].
Access, behaviour, and programme-related determinants
Delayed diagnosis, delayed treatment, and poor adherence can influence malaria morbidity and the persistence of infectious reservoirs [218]C. A mixed-methods study in Uganda, Nigeria, and Côte d’Ivoire used interviews with adults, caregivers, and healthcare professionals, followed by cross-sectional surveys, to identify behavioural barriers to timely access to and adherence with antimalarial treatment [218]C. Community knowledge, perceived risk, and prevention practices also vary geographically: a household survey of 757 people in six East Sumba subdistricts examined malaria-risk perception, mosquito-control practices, and acceptability of spatial repellents across urban/rural and higher/lower-incidence settings [219].
Intervention coverage and implementation may change observed epidemiology. Cluster-randomised trials are particularly useful for malaria because cluster allocation reduces contamination and permits estimation of both direct and indirect community effects [201]. Mathematical transmission modelling combined with baseline prevalence surveys can incorporate the epidemiology of individual trial clusters when planning adequately powered prevalence studies [201]. In Mali, a cluster-randomised substudy assessed malaria positivity and parasite load in infants immediately before and 2 weeks after a single azithromycin mass-drug-administration dose of 20 mg/kg, comparing villages assigned to azithromycin or placebo [202]. In Burkina Faso, SMC delivery mode and age range were compared across programmatic treatment, directly observed treatment in children younger than 5 years, and directly observed treatment in children younger than 10 years, with outcomes including clinical incidence, parasite carriage, and gametocyte carriage in targeted and untargeted individuals [206].
Treatment resistance is a population-level risk modifier because reduced antimalarial efficacy can prolong infection and transmission. A systematic review and meta-analysis of 30 studies from Asia, Africa, and the Americas evaluated artemisinin-based combination therapy response alongside Plasmodium falciparum kelch13 mutations; ACTs retained high pooled efficacy overall, but the distribution of resistance-associated mutations remains an important surveillance concern [209]. Imported falciparum malaria also remains a disproportionate healthcare burden in non-endemic settings such as the United Kingdom, where a multisite cohort evaluated outpatient management of nonsevere adult cases treated with artemether–lumefantrine [208]C.
Interpretation of risk evidence
The strongest directly relevant evidence in this set comes from cluster-randomised or randomised studies of infant prophylaxis, SMC, chemoprevention, and vector-related interventions [201][202][204][205][206][207]. Cross-sectional, surveillance, behavioural, and ecological studies identify plausible associations and vulnerable populations but cannot consistently establish causality [212][214][217][218]C[219][220]. Studies of severe-malaria cardiac dysfunction in Nigerian children, causes of severe morbidity and mortality in Sierra Leonean infants, and multimorbidity among people with HIV in sub-Saharan Africa provide important clinical or comorbidity context, but their abstracts do not establish independent malaria-transmission risk estimates [203][213][215].
| Domain | Evidence from the supplied references | Interpretation |
|---|---|---|
| Age | Infants 4–11 months; infants 6–10 weeks; children 6 months, <5 years, and <10 years were studied [202][203][204][206] | Young children are prominent prevention and outcome populations; risk persists beyond age 5 in some seasonal settings [206] |
| Geography | Studies covered multiple African countries and East Sumba, Indonesia [202][203][204][206][218]C[219] | Risk varies within and between regions [219] |
| Livestock | Spatial cattle distribution was examined for zooprophylaxis versus zoopotentiation [205] | Effects may be context-dependent and extend beyond the household [205] |
| Access and behaviour | Barriers to diagnosis, treatment, adherence, risk perception, and mosquito-control practices were assessed [218]C[219] | Behaviour and health-system access may modify morbidity and transmission [218]C |
| Resistance | Thirty-study review assessed ACT efficacy and kelch13 mutations [209] | Resistance surveillance remains epidemiologically important [209] |
History and Physical Examination
- ▸Fever is a syndrome, not a malaria diagnosis; the pooled prevalence of malaria among AFI cases was 20.2%, so dengue, influenza, chikungunya, bacterial infection, and other causes must remain in the differential. [53][224]
- ▸Ask about travel, residence, mosquito exposure, housing conditions, prior antimalarial treatment, chemoprevention, pregnancy, age, nutrition, and coexisting illness. [221][52][64]
- ▸Treat respiratory distress, neurological involvement, hypotension, oliguria, suspected disseminated intravascular coagulation, and AKI as danger findings associated with increased mortality. [223]
- ▸Use pulse oximetry when available; **SpO2 <90%** defines severe hypoxaemia in the cited primary-care childhood-care framework and warrants urgent referral or escalation. [69]
- ▸Consider malaria co-infection with dengue or bacterial disease and investigate persistent post-malaria symptoms rather than assuming all ongoing fever is malaria. [61][226][232]
Clinical context and presenting complaint
Malaria commonly presents within the broader syndrome of acute febrile illness (AFI), but fever is not specific for malaria. Across low- and middle-income countries, the pooled prevalence of malaria among AFI presentations was 20.2%; dengue, influenza, chikungunya, and hepatitis were also reported causes. [53] In African studies, non-malarial febrile illnesses increasingly include arboviral, bacterial, and other infectious causes, and the differential may vary according to rural or urban setting, inpatient or outpatient status, and whether an outbreak is occurring. [224] Therefore, the history should characterize fever onset, duration, severity, recurrence, associated symptoms, and previous treatment while actively considering alternative diagnoses rather than presuming malaria. [53][224]
Ask about residence, recent travel, and overnight exposure in malaria-endemic areas. Returning travelers may remain undiagnosed despite malaria testing because tropical fever has a broad differential. [229] In Mali, acute undifferentiated fever lasting less than 7 days was investigated for arboviral infection, with dengue identified as an emerging public-health threat. [225]C In Gabon, febrile children were found to have molecular evidence of dengue-virus serotypes and malaria co-infection, illustrating that malaria and arboviral infection may coexist. [61]D In Burkina Faso, 12.64% (12/87) of patients with unexplained acute fever had anti-Rickettsia typhi IgG antibodies after routine evaluation included malaria, dengue, and blood cultures. [227]
Document age, pregnancy status, nutritional status, and relevant comorbidities. Young children are a major high-risk group: a Tanzanian cohort followed 2,397 children over 18 months and found that malaria was associated with a reduction of 0.14 cm/month in height velocity. [222] In children aged 6–30 months with moderate acute malnutrition, a 24-week egg-powder intervention did not improve linear growth or reduce small-intestinal permeability, emphasizing that growth impairment and enteric dysfunction should not automatically be attributed to malaria alone. [51] In Mali, placental malaria was studied in relation to birth size and postnatal growth from birth to age 5 years, including birth length, birth weight, placental weight, linear growth, weight, and body-mass index. [64]D
Exposure and prevention history
Ask about housing, mosquito entry, indoor temperature, smoke exposure, water and sanitation, and household-level vector-control measures. In a cluster-randomized trial in rural Africa, children living in insect-proof, cleaner, cooler, smoke-free Star Homes—with water and sanitation—had 44% less malaria after 3 years than children living in traditional mud and thatched-roof houses. [221] This finding supports recording household environmental conditions as part of the exposure history, although housing history does not establish the diagnosis in an individual patient. [221]
Record use of insecticide-treated nets, chemoprevention, prior antimalarial drugs, adherence, and timing of treatment when known. In Burkina Faso, mass azithromycin was evaluated in children aged 1–59 months in communities receiving seasonal malaria chemoprevention; each eligible child received a single oral 20 mg/kg dose or placebo in the trial. [52] This intervention history should be distinguished from antimalarial treatment and should not be interpreted as diagnostic evidence. [52]
General and focused physical examination
Assess general appearance, mental status, hydration, perfusion, respiratory effort, urine output, and nutritional status. Look specifically for respiratory distress, neurological involvement, hypotension, oliguria, and features suggesting coagulopathy or acute kidney injury (AKI), because these findings identify potentially severe disease. In a systematic review of malaria patients with AKI, respiratory distress syndrome, neurological involvement, disseminated intravascular coagulation, hypotension, and oliguria were associated with mortality; reported odds ratios were 18.50, 12.83, 12.00, 18.23, and 3.41, respectively. [223]
Measure temperature, respiratory rate, pulse, blood pressure, mental status, and oxygen saturation where available. Routine pulse oximetry integrated into primary-care childhood consultations classified severe hypoxaemia as SpO2 <90%; affected children were eligible for referral and were followed for 14-day outcomes. [69]D Hypoxaemia should prompt urgent assessment for respiratory distress and other severe illness, because fever in children may reflect malaria, pneumonia, bacteremia, or another non-malarial infection. [69]D[224][232]
Examine the respiratory system for increased work of breathing and hypoxaemia, the cardiovascular system for hypotension and poor perfusion, and the neurological system for altered consciousness or other neurological involvement. Assess fluid balance and urine production, particularly when AKI is suspected. [223] In febrile children presenting to a Ghanaian teaching hospital, malaria and bacterial infection were both investigated, reflecting the importance of considering bacteremia when fever is present. [232]
Ongoing and post-acute symptoms
Ask about persistent symptoms after treatment or travel, including fatigue, recurrent fever, headache, musculoskeletal symptoms, impaired function, and mental-health effects. A prospective multicentre traveller study followed confirmed chikungunya, dengue, Zika, and falciparum-malaria cases at 1, 3, 6, 12, and 18 months to assess persistent symptoms and quality of life. [226] Persistent illness after malaria should therefore trigger reassessment for relapse or recrudescence where clinically appropriate, treatment complications, co-infection, or an alternative diagnosis; the supplied evidence also shows that undifferentiated fever may remain unexplained after initial evaluation. [226][229]
Diagnostic safety principle
History and examination should determine urgency and the breadth of the differential, but neither fever nor exposure alone confirms malaria. The decline in malaria attribution in some African settings has highlighted previously overlooked non-malarial febrile pathogens. [224] In peripheral settings, integration of malaria rapid-test results with clinical information, C-reactive protein, and white-cell counts has been evaluated to improve management of non-malarial acute febrile illness and antibiotic stewardship. [230] Confirm malaria with appropriate testing while urgently referring or managing patients with SpO2 <90%, respiratory distress, neurological involvement, hypotension, oliguria, or suspected coagulopathy/AKI. [69]D[223]
| Domain | Finding or threshold | Clinical significance |\n|---|---|---|\n| Respiratory | Respiratory distress or SpO2 <90% | Severe illness/hypoxaemia; urgent referral or escalation |\n| Neurological | Neurological involvement or altered mental status | Strongly associated with mortality in malaria-associated AKI |\n| Circulatory | Hypotension or poor perfusion | Strongly associated with mortality in malaria-associated AKI |\n| Renal | Oliguria or suspected AKI | Associated with mortality; assess fluid balance and urine output |\n| Coagulation | Features suggesting disseminated intravascular coagulation | Strongly associated with mortality in malaria-associated AKI |\n| Differential diagnosis | Persistent or undifferentiated fever | Consider dengue, bacteremia, rickettsial disease, and other non-malarial causes |
Clinical Features and Variants
- ▸Imported malaria often begins as a nonspecific febrile illness and may overlap clinically with other mosquito-borne infections, delaying diagnosis in non-endemic regions. [290,294,295,240]
- ▸Non-immune travellers may develop complicated malaria, and conventional severe-malaria criteria may under-recognise clinically important disease in this population. [297]
- ▸Severe malaria can involve neurological, renal, cardiac, haematological, respiratory, and multiple-organ complications; *P. vivax* can also cause severe disease. [215,233,296,297]
- ▸Post-malaria epilepsy may occur after neurological severe malaria even without coma; reported rates after cerebral malaria are approximately **9–16%**. [244]
- ▸AKI is relevant both to acute mortality and to later chronic kidney disease risk in children recovering from severe malaria. [233,293]
- ▸Bacterial coinfection should remain in the differential diagnosis of severe malaria because malaria and sepsis have substantial clinical overlap. [239,292]
General clinical presentation
Malaria is a potentially rapidly progressive febrile illness whose initial manifestations are often nonspecific, including fever and systemic symptoms that overlap with dengue, chikungunya, Zika, yellow fever, Rift Valley fever, and other imported mosquito-borne infections. This overlap is particularly important in non-endemic regions, where limited clinical familiarity may delay recognition. [290] Imported Plasmodium falciparum malaria has been described as diagnostically challenging because of nonspecific manifestations and the possibility of rapid progression to severe disease. [294]C In a post-elimination setting in China, imported cases continued to occur among travellers and people with overseas exposure, with variation in parasite species, travel destinations, clinical manifestations, laboratory findings, and treatment patterns. [295]C
Delayed diagnosis is also documented with P. vivax, particularly in urban or non-endemic settings where clinicians encounter malaria infrequently. Factors associated with delayed diagnosis have been examined among Thai patients and patients from neighbouring countries, with clinical history, healthcare-seeking behaviour, travel or residence, laboratory findings, and outcomes forming the relevant assessment domains. [240]
Uncomplicated and complicated malaria
Uncomplicated malaria refers to parasitaemia without features meeting criteria for severe disease. A recent clinical trial defined acute uncomplicated P. falciparum monoinfection as microscopically confirmed parasitaemia of 1,000–50,000 asexual parasites/µL in one study part and 1,000–150,000 parasites/µL in another, while excluding mixed infection, severe malaria, and major liver abnormalities. [236]C These thresholds were trial eligibility criteria rather than universal diagnostic definitions. [236]C
Complicated or severe malaria encompasses organ-specific complications and may be particularly difficult to classify in non-immune travellers. In a Polish imported-malaria cohort, complicated disease occurred in a substantial proportion of hospitalised imported cases, with the study reporting a commonly cited range of 15–40% and noting that European centres may use broader criteria than the 2023 WHO severe-malaria criteria. [297] The authors specifically highlighted concern that criteria calibrated in semi-immune populations may under-identify severe disease in non-immune travellers. [297]
Severe malaria may involve the brain, kidneys, cardiovascular system, lungs, blood, or multiple organs. Paediatric cerebral malaria is characterised by severe neurological involvement, while a broader neurological phenotype includes impaired consciousness and/or complex seizures without coma, described as malaria with central nervous system signs. [244] Cerebral malaria reflects interactions between parasite sequestration and host endothelial dysfunction; recovery of neurological status and parasite clearance may not coincide with normalisation of vascular biomarkers. [298]
Neurological, renal, and cardiac variants
Neurological disease has important delayed consequences. Approximately 9–16% of children surviving cerebral malaria develop post-malaria epilepsy, and prospective follow-up has also examined epilepsy after severe malaria with central nervous system signs without coma. [244] Thus, epilepsy surveillance should not be restricted to children who presented with coma. [244]
Acute kidney injury (AKI) is an increasingly recognised complication of severe malaria in children. A multinational individual-participant-data meta-analysis used KDIGO serum-creatinine criteria to identify AKI and assess its relationship with inpatient mortality in African children hospitalised with P. falciparum malaria. [233] Prospective Ugandan follow-up further evaluated long-term mortality and chronic kidney disease after severe malaria complicated by AKI, including survivors assessed years after the acute episode. [293] These data support considering renal involvement as both an acute severity marker and a potential precursor to chronic kidney disease. [233][293]
Cardiac abnormalities are also reported in severe paediatric malaria. Echocardiographic assessment in Nigerian children evaluated right- and left-ventricular systolic and diastolic function, including tricuspid annular plane systolic excursion and tricuspid regurgitant velocity, in comparison with age- and sex-matched controls. [215] Severe anaemia, endothelial dysfunction, and recurrent ischaemia–reperfusion injury are proposed contributors to cardiac dysfunction. [215]
Species and epidemiological variants
Although P. falciparum remains strongly associated with severe disease, P. vivax can also cause severe malaria. A mixed retrospective–prospective study in central Ethiopia specifically assessed the emerging predominance of P. vivax and its contribution to severe disease among adults presenting to tertiary emergency departments. [296] The clinical importance of P. vivax therefore extends beyond uncomplicated febrile illness. [296] Relapsing P. vivax infection is a distinct clinical problem caused by persistent liver-stage hypnozoites; contemporary radical-cure algorithms use quantitative G6PD testing to guide primaquine or single-dose tafenoquine selection. [241]C
Coinfection and diagnostic mimics
Severe malaria may coexist with community-acquired bacterial infection. A systematic review and meta-analysis examined community-acquired coinfections in adults with parasitologically confirmed severe imported malaria because clinical overlap with bacterial sepsis can lead to empirical antibiotic use and diagnostic uncertainty. [292] Similar overlap was reported in critically ill children in Kinshasa, where concomitant bacterial sepsis may be under-recognised because malaria and sepsis share clinical and biological manifestations. [239]
Treatment- and prevention-related clinical considerations
Novel treatment studies generally distinguish uncomplicated from severe disease; for example, single-dose cabamiquine–pyronaridine was evaluated only in adolescents and adults with acute uncomplicated P. falciparum monoinfection. [236]C Antimalarial exposure can itself produce clinically relevant abnormalities: hydroxychloroquine-associated cardiotoxicity may include electrical abnormalities and cardiomyopathy, with clinical, electrocardiographic, biopsy, and experimental cardiomyocyte findings investigated in a large clinical series. [238]C
Vaccination reduces but does not eliminate the clinical relevance of malaria surveillance. Contemporary evidence syntheses have evaluated R21/Matrix-M protection against naturally acquired clinical malaria, while routine RTS,S/AS01 deployment in Cameroon has been assessed for effects on severe malaria, uncomplicated malaria, hospitalisation, and mortality. [291][299] Breakthrough infection can also occur despite chemoprophylaxis; postdeployment Plasmodium infection was documented among South Korean soldiers prescribed weekly mefloquine during and after deployment to South Sudan. [301] Advanced molecular testing such as metagenomic next-generation sequencing may complement conventional diagnosis in complex imported P. falciparum cases, but current evidence includes only a five-case series. [294]C
| Variant | Characteristic clinical issue | Evidence |
|---|---|---|
| Uncomplicated malaria | Parasitaemia without severe-disease features; trial eligibility included 1,000–150,000 asexual parasites/µL depending on study part | [236]C |
| Complicated imported malaria | Organ-specific complications; broader definitions may be used in non-endemic centres | [297] |
| Cerebral malaria/CNS malaria | Coma, impaired consciousness, and/or complex seizures; risk of later epilepsy | [244][298] |
| Renal severe malaria | AKI during admission, with possible later chronic kidney disease | [233][293] |
| Cardiac severe malaria | Ventricular systolic or diastolic dysfunction and electrical abnormalities | [215][238]C |
| Severe P. vivax malaria | Severe disease is not restricted to P. falciparum | [296] |
| Malaria with bacterial coinfection | Clinical overlap with bacterial sepsis may delay appropriate antimicrobial treatment | [239][292] |
| Relapsing P. vivax malaria | Hypnozoite-associated relapse requiring G6PD-guided radical cure | [241]C |
Diagnosis and Workup
- ▸Use parasitological testing rather than clinical symptoms alone; the supplied evidence emphasizes microscopy, RDTs, and molecular assays [255,259,261,264].
- ▸Microscopy can confirm monoinfection and quantify parasite density; one trial used **1,000–50,000 parasites/µL** and **1,000–150,000 parasites/µL** eligibility ranges [236].
- ▸Consider molecular testing for suspected submicroscopic, asymptomatic, recurrent, or surveillance-detected infection [255,260,264].
- ▸Investigate alternative causes of fever when malaria testing is negative because non-malarial febrile illnesses are prevalent [267].
- ▸Consider species confirmation where zoonotic *P. knowlesi* is possible [260,268].
- ▸Assess complications in severe malaria and consider targeted echocardiography when cardiac dysfunction is suspected, especially in children [215].
- ▸In pregnancy, evaluate parasite persistence and local resistance patterns, including relevant *dhfr* and *dhps* mutations [253,256].
Diagnostic approach
The diagnostic approach should begin with clinical assessment of febrile illness, exposure and transmission context, age, pregnancy status, and features suggesting severe disease; however, the supplied studies do not provide a validated symptom-based diagnostic algorithm or severity threshold. The evidence instead supports prompt parasitological testing because malaria may be asymptomatic or submicroscopic and because fever is frequently caused by non-malarial illnesses. In Tanzania, patients with fever and a negative malaria rapid diagnostic test (RDT) were operationally classified as having a non-malarial febrile illness, and such illnesses were mapped across all 26 regions and 86 health facilities, demonstrating the importance of investigating alternative causes when malaria testing is negative [267].
Initial parasitological testing
Blood-film microscopy remains an important reference method in the cited studies. In a multicentre antimalarial trial, acute uncomplicated Plasmodium falciparum malaria required microscopically confirmed monoinfection with parasite densities of 1,000–50,000 asexual parasites/µL in one study part and 1,000–150,000 parasites/µL in another [236]C. Microscopy was also used to identify and treat asymptomatic infections in Kenyan schoolchildren, with assessments performed at baseline, 4 weeks, and 8 weeks [255]. These studies illustrate that microscopy can provide parasite detection, species information, and parasite-density estimates, but the supplied references do not establish sensitivity, quality-control requirements, or a universal microscopy threshold for treatment.
Malaria RDTs are widely used in routine care and surveillance. A Republic of Congo survey described mRDTs as essential for early detection and effective management, while identifying limited healthcare-worker practical knowledge as a barrier to reliable diagnostic practice [259]. A prospective Indian evaluation enrolled 1,799 patients with suspected malaria and compared the SD BIOSENSOR STANDARD Q Malaria/CRP Duo Test with expert microscopy for malaria detection [261]. The same test also detects C-reactive protein, a potential host marker for distinguishing bacterial from non-bacterial illness, although the supplied evidence does not provide performance estimates or establish CRP as a malaria diagnostic criterion [261].
Molecular testing and low-density infection
Molecular assays are useful when parasite densities are low or when microscopy and RDT results are negative despite epidemiological or clinical concern. In Ghana, malaria assessment combined mRDT, blood-smear microscopy, and LAMP-PCR for parasite detection and species identification; the study specifically investigated submicroscopic P. falciparum infection and molecular markers of antimalarial resistance [264]. In western Kenya, quantitative PCR for P. falciparum (PfqPCR) was used alongside microscopy to measure parasitaemia longitudinally in schoolchildren with asymptomatic infection [255]. In rural Malaysian Borneo, surveillance for Plasmodium infection included methods capable of identifying submicroscopic carriage in communities exposed to zoonotic P. knowlesi [260]. These findings support reflex or confirmatory molecular testing in suspected low-density, asymptomatic, recurrent, or elimination-surveillance infections, but the references do not define a standardized testing sequence or positivity threshold.
Species identification is clinically important in Southeast Asia because P. knowlesi is zoonotic and can cause potentially life-threatening haematological complications, including thrombocytopenia [260][268]D. In Faladie, Mali, mosquito species and Plasmodium positivity were characterized using molecular methods, including PCR-RFLP for Anopheles gambiae complex identification and quantitative PCR targeting parasite 18S genes [263]. These vector studies are not patient diagnostic protocols, but they reinforce the value of molecular species and transmission investigations where zoonotic or atypical malaria is possible [260][263].
Assessment for complications and associated conditions
A positive malaria test should be accompanied by assessment for complications, particularly in children and pregnant patients. In Nigerian children with severe malaria, transthoracic echocardiography assessed right- and left-ventricular systolic and diastolic function, including tricuspid annular plane systolic excursion and tricuspid regurgitant velocity, because cardiac dysfunction may accompany severe disease [215]. The cited study included 100 children with severe malaria and 100 matched controls, but it does not establish echocardiography as routine testing for every patient [215].
Pregnancy requires particular attention to persistent parasitaemia and possible antimalarial resistance. A Northern Ugandan cohort evaluated P. falciparum resistance-associated mutations in dhfr (N51I, C59R, S108N, I164L) and dhps (A437G, K540E, A581G) in women receiving intermittent preventive treatment [256]. A Northern Nigerian phase IV trial protocol likewise focuses on parasitological efficacy and compares sulphadoxine-pyrimethamine, dihydroartemisinin-piperaquine, and combination therapy during pregnancy [253]. These studies support consideration of parasite persistence and local resistance surveillance in antenatal and treatment workups, although they do not provide a clinical resistance-testing algorithm.
Interpreting negative or discordant results
A negative RDT does not exclude every low-density infection: submicroscopic infections were specifically investigated in Ghana and Malaysian Borneo using molecular methods [260][264]. Conversely, a positive malaria test should not automatically be assumed to explain every febrile illness, because non-malarial febrile illnesses were common enough in Tanzania to warrant nationwide characterization among RDT-negative patients [267]. Discordant results should therefore prompt review of specimen quality, timing, parasite density, species identification, exposure setting, and alternative diagnoses; the cited literature supports these considerations but does not quantify diagnostic accuracy or prescribe a single confirmatory pathway [259][261][260][264][267].
| Method or evaluation | Use illustrated by the references |
|---|---|
| Blood-film microscopy | Confirmation of acute uncomplicated P. falciparum, parasite-density estimation, and detection of asymptomatic infection [236]C[255] |
| Malaria RDT | Routine early detection; interpretation requires attention to healthcare-worker training and alternative causes of fever [259][267] |
| RDT plus CRP | Concurrent malaria and CRP testing evaluated against expert microscopy in 1,799 suspected cases in India [261] |
| LAMP-PCR | Detection and species identification of submicroscopic P. falciparum in Ghana [264] |
| PfqPCR | Quantification of P. falciparum parasitaemia in Kenyan children [255] |
| Molecular surveillance | Detection of low-density infection and investigation of zoonotic malaria in Malaysian Borneo [260] |
| Echocardiography | Evaluation of cardiac function in children with severe malaria [215] |
| Resistance genotyping | Assessment of dhfr and dhps mutations in pregnant women receiving preventive treatment [256] |
Management of Malaria
- ▸Intravenous artesunate (2.4 mg/kg) is the gold standard for severe malaria, significantly reducing mortality compared to older agents.
- ▸Radical cure for P. vivax requires primaquine, but its efficacy is contingent on the patient's CYP2D6 metabolic activity score.
- ▸Artemisinin-based combination therapies (ACTs) must be used to treat uncomplicated malaria to delay the spread of pfk13-mediated resistance.
The of malaria requires a rapid, stratified approach based on disease severity, infecting species, and regional resistance patterns [130][133]D. The primary goal is the rapid elimination of the asexual blood-stage parasite to prevent progression to severe disease and death, while secondary goals include the elimination of latent liver stages (hypnozoites) in P. vivax and P. ovale infections to prevent relapse [27][92]C. Current strategies are increasingly challenged by the emergence of artemisinin partial resistance (ART-R), characterized by delayed parasite clearance and mutations in the pfk13 gene [130][134]D.
Step 1: Initial Assessment and Severity Classification
Immediate triage is essential to distinguish between uncomplicated and severe malaria. Patients must be assessed for clinical danger signs, including impaired consciousness (cerebral malaria), respiratory distress, severe anemia, or renal impairment [89][92]C.
- Severe Malaria Criteria: Presence of P. falciparum (or occasionally P. vivax) parasitemia plus one or more complications: Glasgow Coma Scale <11, hemoglobin <7 g/dL, or serum creatinine >265 μmol/L [89][92]C.
- Disposition: Patients with severe malaria require immediate admission to an Intensive Care Unit (ICU) or high-dependency unit for parenteral therapy [84][89]. Children and non-immune travelers are at the highest risk for rapid deterioration [98]D.
- Special Populations: Pregnant women require integrated care to manage multi-morbidity, as malaria significantly increases maternal and infant mortality [139]D.
Step 2: Management of Uncomplicated Malaria
Artemisinin-based Combination Therapy (ACT) is the first-line treatment for uncomplicated P. falciparum malaria [133]D[141]D. ACTs utilize the rapid action of artemisinin derivatives to reduce the parasite biomass by approximately 10,000-fold per cycle, paired with a longer-acting partner drug to eliminate residual parasites [138]D[143]D.
- First-line Regimen: Artemether-lumefantrine (AL) (e.g., 20/120 mg tablets, weight-based dosing twice daily for 3 days) or Artesunate-sulfadoxine-pyrimethamine (AS+SP) [134]D[141]D.
- Mechanism of Action: Artemisinins induce widespread protein damage, which triggers the parasite's 26S proteasome for degradation; inhibitors of this proteasome have shown synergy with artemisinins [143]D.
- Emerging Alternatives: In areas with high resistance, triple combinations such as Fosmidomycin (30 mg/kg) + Clindamycin (10 mg/kg) + Artesunate are being evaluated to ensure efficacy [127].
Step 3: Management of Severe Malaria
Severe malaria is a medical emergency. Parenteral treatment should be initiated immediately upon suspicion, even before parasitological confirmation if delays are expected [84][92]C.
- Drug of Choice: Intravenous (IV) Artesunate 2.4 mg/kg at 0, 12, and 24 hours, then daily until the patient can tolerate oral medication [89][92]C.
- Reasoning: IV artesunate is superior to quinine in reducing mortality and has a better safety profile, though clinicians must monitor for delayed post-artesunate [89].
- Transition: Once the patient can swallow, complete a full 3-day course of an oral ACT [92]C.
Step 4: Radical Cure and Relapse Prevention
For P. vivax and P. ovale, eliminating the blood-stage infection is insufficient. Latent hypnozoites in the liver must be eradicated to prevent relapses [27].
- Protocol: Administer Primaquine 0.25–0.5 mg/kg daily for 14 days [27][92]C.
- Clinical Reasoning: Primaquine efficacy is highly dependent on host metabolism. Patients with reduced CYP2D6 activity (Activity Score <1.0) have a significantly higher risk of treatment failure and relapse because they cannot effectively convert primaquine into its active metabolites [27].
- Warning: G6PD testing is mandatory before primaquine administration to avoid severe hemolysis.
Step 5: Monitoring and Resistance Surveillance
Treatment success must be confirmed through clinical and parasitological follow-up.
- Day 3 Monitoring: The presence of parasitemia 72 hours after starting ACT (Day 3) is a hallmark of artemisinin partial resistance [133]D[134]D.
- Molecular Markers: Surveillance should track mutations in pfk13 (artemisinin), dhfr/dhps (antifolates), and pfcrt (chloroquine) [130][141]D[144]D. For instance, the dhfr triple mutant N51I/C59R/S108N is now nearly fixed in many regions, rendering older drugs like pyrimethamine ineffective [134]D[146]D.
Treatment Failure Protocol
If first-line ACT fails (defined as recurrence of symptoms and parasitemia within 28–42 days):
- Verify Adherence: Confirm the patient completed the full course and did not vomit the dose.
- Switch ACT: Use an alternative ACT with a different partner drug (e.g., switch from AL to Dihydroartemisinin-piperaquine) [133]D.
- Escalation: In cases of multi-drug resistance, consider experimental protocols or novel agents like PfDHODH inhibitors or 3-hydroxypropanamidines if available through clinical trials [122]D[145]D.
What NOT to Do
- Do NOT use monotherapy: Using artemisinins or partner drugs alone rapidly accelerates the selection of resistant strains [130][133]D.
- Do NOT ignore drug-drug interactions: 4-aminoquinolines (like chloroquine) can antagonize artemisinin action by blocking heme iron reactivity, particularly during the early ring stage of the parasite cycle [138]D.
- Do NOT delay parenteral therapy: In severe malaria, oral medication is unreliable due to potential vomiting and impaired absorption [84].
| Drug | Standard Dose | Route | Indication | Key ADR / Considerations | Evidence Level |
|---|---|---|---|---|---|
| Artesunate | 2.4 mg/kg | IV | Severe Malaria | Delayed hemolysis; superior to quinine | 1b [89][92]C |
| Artemether-Lumefantrine | 20/120 mg (weight-based) | Oral | Uncomplicated P. falciparum | Must be taken with fatty food for absorption | 1b [134]D[141]D |
| Primaquine | 0.25-0.5 mg/kg | Oral | Radical cure (P. vivax/ovale) | Hemolysis in G6PD deficiency; requires CYP2D6 | 2b [27][92]C |
| Fosmidomycin | 30 mg/kg | Oral | Uncomplicated (Combination) | Used with clindamycin/artesunate in resistance | 1b [127] |
| LAFIS10 | 15-125 mg/kg | IP (Exp) | Experimental | Piperazine derivative; nanomolar potency in vitro | 5 [148]D |
Supportive Care and Complication Management
- ▸Confirm the diagnosis and actively investigate alternative or concurrent causes of coma and fever; malaria does not exclude bacteremia or another neurological infection [157,232].
- ▸In selected children with CM and MRI-defined severe brain swelling (BVS 6–8), early ventilation and 3% hypertonic saline have been directly evaluated, but the supplied evidence does not establish a mortality benefit [269].
- ▸Monitor temperature and seizures closely; both are associated with neurological outcome risk [153].
- ▸Use individualized fluid resuscitation and reassess frequently because pediatric fluid-strategy trials showed no significant mortality difference between several approaches [151].
- ▸Follow survivors for epilepsy, neurological deficits, cognition, and kidney disease, including children who had severe malaria without coma [237,244,293].
Immediate assessment and supportive priorities
Severe malaria requires urgent assessment for coma, seizures, respiratory distress, severe anemia, shock, metabolic derangement, renal injury, and alternative causes of fever or impaired consciousness. Cerebral malaria (CM) is commonly defined in the cited pediatric trial by Blantyre Coma Score ≤2, Plasmodium falciparum parasitemia, and absence of another explanation for coma [269]. Febrile coma should not automatically be attributed to malaria: prospective Malawian data evaluated pathogen-specific blood and cerebrospinal-fluid testing because non-malarial causes may be under-recognized in settings where malaria prevalence is changing [157]. Bacteremia is another important competing or coexisting diagnosis in febrile children, since malaria may be presumed without confirmation and bacterial infection can be missed [232]. Diagnostic reassessment is therefore warranted when the clinical course, laboratory findings, or neurological examination is atypical [157][232].
Disease-specific antimalarial treatment remains central; the 2026 randomized trial evaluated interventions in addition to supportive care and antimalarials rather than as replacements for them [269]. Management should be adapted to available monitoring, with repeated neurological, respiratory, hemodynamic, glucose, temperature, urine-output, and renal assessments because severe malaria may involve several organ systems [99]D[151][293].
Cerebral swelling and respiratory failure
In children with CM and MRI-defined highly increased brain volume, the phase 3 trial enrolled those with a brain-volume score (BVS) of 6–8 and randomized them to early intubation with mechanical ventilation, intravenous 3% hypertonic saline, or usual care; the primary outcome was 7-day mortality, with neurological morbidity assessed as a secondary outcome [269]. These interventions should therefore be regarded as specialized, trial-informed strategies for selected children with severe brain swelling, not routine treatment for every child with CM. The available citation identifies the trial design and target population but does not provide sufficient outcome data here to support a mortality benefit for early ventilation or hypertonic saline [269]. Airway protection and ventilation remain appropriate when consciousness or respiratory function is inadequate, but decisions should consider local critical-care capacity and the risks of intubation and ventilation [269].
Respiratory distress is one of the major clinical forms of severe malaria and was included in prospective pediatric outcome cohorts, alongside CM, complicated seizures, severe malarial anemia, and prostration [158][175]D[237]. Children with respiratory compromise require close monitoring for progression and evaluation for alternative or additional diagnoses, including bacterial infection [232].
Fever and seizures
Temperature and seizures are clinically important because higher maximum temperature and seizures have been associated with neurological sequelae in children surviving CNS malaria [153]. A randomized trial compared scheduled acetaminophen plus ibuprofen with usual care, in which acetaminophen was given only at ≥38.5°C, among children aged 2–11 years with CNS malaria; children with creatinine >1.2 mg/dL were excluded [153]. This evidence supports careful temperature measurement and seizure surveillance, but the cited abstract does not provide sufficient results to recommend aggressive scheduled dual antipyretic therapy as routine practice [153]. Ibuprofen should be used cautiously or avoided when renal injury, dehydration, or shock is present, particularly because acute kidney injury is an important complication of severe malaria [153][293].
Neurological follow-up should include assessment for persistent deficits, epilepsy, cognition, behavior, movement disorders, hearing or visual problems, and school or developmental functioning. At discharge, neurological deficits were more frequent after CM than after non-cerebral severe malaria (38.9% versus 9.1%), although persistent deficits at 12 months were uncommon in the cited Ugandan cohort [237]. Post-malaria epilepsy screening is warranted even after severe malaria with neurological signs but without coma, because epilepsy risk is not confined to classic CM [244]. Cerebellar ataxia was the most frequently reported malaria-associated movement disorder in a systematic review of case reports, series, and cohorts; P. falciparum accounted for 75% of individual cases and P. vivax for 20% [150].
Anemia, shock, and kidney injury
Severe malarial anemia, respiratory distress, complicated seizures, prostration, and CM may coexist, and each should be actively sought during admission [158][175]D. Fluid resuscitation should be individualized rather than automatically liberal. A systematic review of 12 pediatric trials involving 3,526 children with severe infection, with or without malaria, found no significant mortality difference across the evaluated fluid strategies, including balanced crystalloids versus normal saline and restricted versus liberal boluses [151]. In children with shock, reassess after each bolus for perfusion, respiratory deterioration, urine output, and signs of fluid overload [151].
Acute kidney injury (AKI) is a major complication requiring serial creatinine, electrolyte, acid–base, urine-output, and fluid-balance assessment [293]. Long-term follow-up data from Ugandan cohorts specifically examined mortality and chronic kidney disease after severe malaria-associated AKI, underscoring that renal recovery should not be assumed at discharge [293]. Survivors with AKI should receive renal follow-up when feasible, including reassessment of kidney function and blood pressure [293].
Discharge planning and survivorship
Discharge should include neurological, cognitive, renal, and functional review, caregiver education, and a clear plan for return if seizures, altered consciousness, fever, respiratory symptoms, reduced urine output, or recurrent weakness develops. Children surviving severe falciparum malaria had increased post-discharge hospitalization risk in a prospective 12-month cohort [158]. CM and severe malarial anemia were associated with long-term cognitive impairment, whereas the cited study did not identify the same association for other severe-malaria syndromes [175]D. Severe malarial anemia has also been associated with decreased long-term household wealth, emphasizing the need to consider rehabilitation, school reintegration, caregiver burden, and social support in survivorship planning [270].
| Complication or risk | Monitoring and follow-up focus | Evidence |
|---|---|---|
| Cerebral swelling | Serial neurological assessment; consider MRI-based assessment where available; specialist airway and neurocritical-care review for severe swelling | [269] |
| Fever and seizures | Repeated temperature measurement, seizure recognition and treatment, and neurological follow-up | [153][244] |
| Respiratory distress | Respiratory examination, oxygenation, and escalation assessment; investigate coexisting infection | [158][232] |
| Shock or dehydration | Individualized fluids with reassessment for perfusion and fluid overload | [151] |
| Acute kidney injury | Creatinine, electrolytes, urine output, acid–base status, fluid balance, and post-discharge renal review | [153][293] |
| Neurological sequelae | Screening for deficits, epilepsy, movement disorders, cognition, and school-function problems | [150][175]D[237][244] |
Prevention and Screening
- ▸ITN impact depends on access, use, and retention; these vary substantially by subnational setting and may justify tailored distribution strategies. [287]
- ▸IR3535 spatial repellents are being evaluated as a complementary option where insecticide resistance threatens conventional vector control, but the supplied evidence does not establish effect size. [285]
- ▸SMC strategies under evaluation include directly observed administration, extension from children younger than 5 years to younger than 10 years, and a fifth monthly cycle in prolonged transmission seasons. [206][262]
- ▸SP resistance markers in pfdhfr and pfdhps are widespread and regionally variable, supporting molecular surveillance when designing chemoprevention programs. [278]
- ▸DHP was associated with lower maternal and placental malaria than SP in a meta-analysis, whereas effects on fetal loss, low birth weight, and preterm birth were inconclusive. [279]
- ▸CIS43LS analyses reported 80% liver-stage protection for 4–6 months, with a protective correlate above approximately 64 μg/mL. [288]
- ▸ANC1 malaria prevalence can be incorporated into mechanistic models to estimate seasonal community burden and clinical incidence. [283]
- ▸PDMC is being studied through health-system delivery and adherence-support strategies for children discharged after severe anemia or severe malaria. [251]
Overview
Malaria prevention increasingly uses combinations of vector control, chemoprevention, vaccination, monoclonal antibodies, and context-specific delivery systems. The available 2026 evidence supports tailoring prevention to transmission seasonality, age, pregnancy, post-discharge vulnerability, insecticide resistance, local parasite resistance, and the operational quality of delivery. [206][206][278][287]D[289]D
Vector control and household protection
Insecticide-treated nets (ITNs) remain an impactful and cost-effective malaria-control intervention, but their practical effect depends on household access, use, and retention. In six African countries—Burkina Faso, Ghana, Malawi, Mali, Mozambique, and Senegal—subnational heterogeneity in these measures was assessed to inform whether more efficacious nets or more frequent distribution could improve control. [287]D Mass campaigns commonly distribute ITNs every three years, whereas retention may be substantially shorter; consequently, subnational distribution strategies should account for local patterns of access, use, and loss. [287]D
Spatial repellents are being evaluated as complementary tools where insecticide resistance limits conventional vector control. In a randomized before-after control-intervention trial in rural central Mozambique, household spraying with IR3535 was compared with no repellent, with polymerase-chain-reaction malaria prevalence in children younger than 5 years as an outcome. [285] The available abstract describes the evaluation design but does not provide sufficient results to establish the magnitude or duration of protection. [285]
Prevention behavior is also influenced by health literacy and implementation conditions. A household study in Gabon examined health literacy in relation to regular bed-net use, uptake of indoor residual spraying, treatment-seeking, medication adherence, and other malaria behaviors. [281] A community survey in Ethiopia assessed prevention practices during armed conflict, a setting in which maintaining continuous prevention may be particularly difficult. [282] In Nigeria, caregiver-perceived quality of door-to-door seasonal malaria chemoprevention (SMC) delivery was examined in relation to caregiver engagement, at-home amodiaquine adherence, retention of child record cards, and prevention practices. [286]
Chemoprevention
SMC with sulfadoxine-pyrimethamine (SP) plus amodiaquine is established in African programs for children aged 3–59 months. [206][286] A cluster-randomized trial in Burkina Faso compared programmatic SMC in children younger than 5 years with directly observed treatment (DOT), and also evaluated DOT-based SMC extended to children younger than 10 years. Outcomes included clinical malaria incidence, parasite carriage, and gametocyte carriage in both targeted and untargeted individuals. [206] The abstract does not provide the trial’s numerical results; therefore, extension to older children or replacement of programmatic administration with DOT should be considered evidence-generating rather than universally assumed to be superior. [206]
Where transmission seasons are prolonged, adding a fifth monthly SMC cycle has been evaluated in Niger. A quasi-experimental difference-in-differences study compared nine health centers implementing five cycles with ten centers continuing four cycles, using routine data from 2020–2023 and assessing malaria incidence and use of diagnostic and treatment services. [262] Because this was non-randomized and used a comparison-district design, its findings require cautious interpretation when applied to other settings. [262]
SP remains central to SMC, intermittent preventive treatment in pregnancy, and intermittent preventive treatment in infancy, despite widespread antifolate resistance. [278] A systematic review of 95 studies published from 2010 through 2025 characterized regional and temporal patterns of P. falciparum pfdhfr and pfdhps resistance markers in East and West Africa. [278] Molecular surveillance should therefore accompany decisions about continued SP use and chemoprevention policy. [278]
Pregnancy-specific prevention is being compared with alternative regimens. A systematic review and meta-analysis found that dihydroartemisinin–piperaquine (DHP), compared with SP, was associated with lower maternal malaria infection (RR 0.22), placental infection (RR 0.27), and maternal anemia (RR 0.84); reductions in fetal loss, low birth weight, and preterm birth were not statistically conclusive in the reported estimates. [279] These findings support consideration of DHP as a potential alternative where appropriate, while regimen selection must account for local guidance, resistance, safety, adherence, and the limitations of pooled evidence. [279]
Children discharged after hospitalization for severe anemia or severe malaria remain at high risk of readmission and death. Post-discharge malaria chemoprevention (PDMC) has been reported to reduce mortality and readmissions and is recommended by WHO; an implementation trial in Benin is evaluating delivery strategies and adherence support through existing health systems. [251]D
Vaccines and long-acting biologics
RTS,S/AS01 and R21/Matrix-M provide active immunity through responses directed against the circumsporozoite protein, including polyclonal antibody and CD4-positive T-cell responses. [289]D A clinical trial evaluating RTS,S in combination with SMC showed substantial protection over five years; genotyping found less complex infections among recipients of both interventions than among those receiving either intervention alone, and assessed whether infecting parasites matched the vaccine construct’s circumsporozoite sequence. [277]
Long-acting monoclonal antibodies provide immediate passive protection and may complement vaccines. CIS43LS targets a conserved hinge region of the P. falciparum circumsporozoite protein and has demonstrated 80% protection against liver-stage invasion for 4–6 months in controlled human malaria infection analyses; protection correlated with antibody concentrations above approximately 64 μg/mL, and subcutaneous administration may permit lower doses. [288]D Pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modelling are being used to relate exposure and time above protective concentrations to duration of protection for vaccines and antibodies. [289]D
Screening, surveillance, and evaluation
Malaria prevalence at the first antenatal-care visit (ANC1) can provide longitudinal information on malaria burden in pregnancy and correlates with cross-sectional community prevalence. A validated mechanistic, age-structured transmission model was developed to determine whether monthly ANC1 prevalence could recover seasonal patterns of clinical incidence for subnational programmatic decisions. [283]
Cluster-randomized trials are important for estimating both direct and indirect community effects while limiting contamination between intervention and control areas. A modelling framework combining statistical and dynamical transmission models uses cluster epidemiology and baseline prevalence surveys to guide sample-size calculations for trials with malaria prevalence outcomes. [201]
Iron and multiple-micronutrient supplementation are also being evaluated alongside malaria chemoprevention in young children. The IRMA randomized clinical trial enrolled 6-month-old infants in rural malaria-endemic Malawi to assess functional outcomes and whether universal iron interventions with chemoprevention are safe with respect to infection risk. [204] The study addresses concerns that iron could increase infection risk, but the supplied abstract does not provide final outcome estimates. [204]
Prevention programs should therefore pair intervention coverage monitoring with parasitological surveillance, resistance-marker surveillance, adherence assessment, and outcome measurement in the populations at greatest risk. [201][278][281][283][286][287]D
| Approach | Population or setting | Evidence focus |
|---|---|---|
| ITNs | African subnational settings | Access, use, retention, and distribution frequency; heterogeneity assessed in six countries. [287]D |
| IR3535 spatial repellent | Rural central Mozambique | Randomized before-after evaluation using PCR prevalence in children younger than 5 years. [285] |
| SMC with SP plus AQ | Children aged 3–59 months; Burkina Faso trial also assessed children younger than 10 years | Programmatic delivery, DOT, age extension, parasite carriage, and gametocyte carriage. [206][286] |
| Pregnancy chemoprevention | Pregnant women | DHP versus SP: lower maternal and placental infection with DHP in pooled evidence. [279] |
| PDMC | Children discharged after severe anemia or severe malaria | Delivery strategies and adherence support under evaluation in Benin. [251]D |
| Vaccines and monoclonal antibodies | Populations at risk in endemic regions | RTS,S/AS01, R21/Matrix-M, and long-acting antibodies provide active or passive protection. [277][288]D[289]D |
| ANC1 screening/modeling | Pregnant women attending first ANC | Prevalence used to infer seasonal community burden and clinical incidence. [283] |
References
- [1]
Bonacolta AM, Li L, Del Campo J et al.. “Endosymbiotic Apicomplexans of Marine Holobionts: Microbial Parasites in a Warming Ocean.” Integrative and comparative biology (2026). PMID: 41665867 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [2]
Nguyễn ĐTD, Lê HG, Võ TC et al.. “Genetic polymorphism and natural selection of apical membrane antigen-1 in Plasmodium malariae isolated from Vietnam.” BMC infectious diseases (2026). PMID: 41776459 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Clinical Features and Variants - [3]
Voges K, Dias GR, Dupim EG et al.. “Anopheles (Kerteszia) cruzii, the main malaria vector in the Brazilian Atlantic Forest, is a complex of at least five cryptic species.” Communications biology (2026). PMID: 41741717 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [4]
Lawal MS, Hayashida K, Sugi T et al.. “Detection of novel Pegivirus C genome in an unexplained febrile outbreak, Gombe State, Nigeria, 2024 by enhanced mNGS approach.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 41667020 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, History and Physical Examination - [5]
Rubio-Palis Y, Corredor-Medina C, Lenhart AE et al.. “Anopheles species complexes from Guyana and Venezuela malaria endemic areas using COI sequences.” Malaria journal (2026). PMID: 41547760 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [6]
Rattanapitoon NK, Gordon CN, Charoenphon N et al.. “CXCL10high Microglia in Cerebral Malaria: Toward Translational Validation.” CNS neuroscience & therapeutics (2026). PMID: 41518083 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [7]
Daniyan MO, Singh H, Blatch GL. “Plasmodium knowlesi Heat Shock Protein 90s: In Silico Analysis Reveals Unique Druggable Structural Features.” International journal of molecular sciences (2025). PMID: 41465491 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [8]
Traoré H, Gnambani EJ, Hien DFS et al.. “Molecular characterization of potential Plasmodium-Blocking Serratia spp. bacteria in field-caught malaria mosquito in Burkina Faso.” Parasites & vectors (2025). PMID: 41423613 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [9]
Jote K, Gebrehiwot Y, Abebe A et al.. “Preliminary analysis of the conserved Plasmodium falciparum k13 gene in Arbaminch and Mirab Abaya, Ethiopia.” Malaria journal (2025). PMID: 41331631 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [10]
Hossain MS, Anjum MF, Rabbani MA et al.. “Bacillus altitudinis: a sustainable mosquito controlling biopesticide isolated from the rhizospheric soil of Nypa fruticans in mangrove forest.” BMC microbiology (2025). PMID: 41225312 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [11]
Pacheco MA, Miller EA, Harl J et al.. “Haemoproteus syrnii and other haemosporidians infecting owls from North America.” Malaria journal (2025). PMID: 41163075 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [12]
Dharmayanthi AB, Pratama R, Sánchez KL et al.. “The mitochondrial genome sequence of the Bornean orang-utan (Pongo pygmaeus) malaria parasite, Plasmodium pitheci.” Malaria journal (2025). PMID: 41063129 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [13]
Wandera HT, Nattoh G, Kiboi D et al.. “Investigation of prevalence and phylogenetic classification of Microsporidia MB and insecticide target site insensitivity resistance mutations in Anopheles gambiae s.l. and Anopheles funestus mosquitoes from Busia, Kenya.” BMC microbiology (2025). PMID: 41039202 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [14]
Pusawang K, Zhong D, Sriwichai P et al.. “Genetic variation in olfactory pathways associated with host-seeking behavior in natural populations of Anopheles minimus, a primary malaria vector in western Thailand.” Parasites & vectors (2025). PMID: 40993777 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [15]
Teixeira KS, Moreira HM, Roca TP et al.. “Reemergence of Oropouche in the Brazilian Amazon: A phylodynamic and phylogenetic analysis.” Travel medicine and infectious disease (2025). PMID: 40716624 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [16]
Bouyssou I, Golassa L, Vigan-Womas I et al.. “Genomic analysis of Plasmodium vivax field isolates circulating in sub-Saharan Africa.” Communications biology (2025). PMID: 40624365 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [17]
Usmani S, Gebhardt ME, Simubali L et al.. “Phylogenetic taxonomy of the Zambian Anopheles coustani group using a mitogenomics approach.” Malaria journal (2025). PMID: 40597261 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [18]
Kimita G, Collins J, Mutai B et al.. “Detection of zika virus disease caused by the Asian lineage of the zika virus at Kenya's Lamu island.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2025). PMID: 40010630 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [19]
Postigo-Hidalgo I, Magassouba N, Krüger N et al.. “Elucidating Infectious Causes of Fever of Unknown Origin: A Laboratory-Based Observational Study of Patients with Suspected Ebola Virus Disease, Guinea, 2014.” The Journal of infectious diseases (2025). PMID: 39928049 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [20]
Bodawatta KH, Albrecht T, Krausová S et al.. “Cophylogeny, narrow host breadth and local conditions drive highly specialized bird-haemosporidian associations in West-Central African sky islands.” Proceedings. Biological sciences (2025). PMID: 39837510 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [21]
Manu GP, Bonney JHK, Bawa FK et al.. “Reduced COVID-19 severity in Africa: a systematic review of host genetic and immunological responses to SARS-CoV-2 infection.” Frontiers in immunology (2026). PMID: 41993206 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [22]
Wilczyńska W, Akilimali A, Korzeniewski K. “Human Filariasis in Africa (2000-2025): Changing epidemiology, uneven diagnostic progress, and persistent neglect.” PLoS neglected tropical diseases (2026). PMID: 41945600 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [23]
Sadhewa A, Panggalo LV, Nanine I et al.. “G6PD deficiency in Indonesia: a systematic review and update of prevalence and variant maps in the context of malaria elimination.” The Lancet regional health. Western Pacific (2026). PMID: 41953713 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [24]
Hassan U, Siddiqa A, Zhu Y et al.. “Prevalence of Plasmodium falciparum coinfection with Schistosoma haematobium and Schistosoma mansoni among children in sub-Saharan Africa: a systematic review and meta-analysis.” Malaria journal (2026). PMID: 41935296 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Clinical Features and Variants, Diagnosis and Workup - [25]
Penjor K, Thapa B, Tsheten T et al.. “Estimating the burden of imported malaria in the Asia Pacific Region: A Systematic review and meta-analysis.” Journal of travel medicine (2026). PMID: 41934231 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [26]
Ramadan S, Talkhan A, Mansour A et al.. “Efficacy of ivermectin for malaria vector control: a systematic review and meta-analysis of randomized clinical trials.” Malaria journal (2026). PMID: 41917922 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [27]
Corder RM, Puça MCSB, Prete CA et al.. “Reduced cytochrome P-450 (CYP) 2D6 activity and Plasmodium vivax malaria risk in Amazonians: A retrospective, population-based cohort study.” PLoS neglected tropical diseases (2026). PMID: 41894411 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors, Management - [28]
Diallo EM, Loum MA, Diallo OO et al.. “Model-Based Assessment of the Effects of Selective Free Healthcare and Differentiated Diagnosis on Malaria Burden in the Republic of Guinea.” Tropical medicine & international health : TM & IH (2026). PMID: 41994979 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Management - [29]
Peng PY, Xu L, Duan HY et al.. “One health perspectives on the epidemiological features and changing incidence of natural focus and vector-borne infectious diseases in China: An observational trend study.” One health (Amsterdam, Netherlands) (2026). PMID: 41993771 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [30]
Rahman MS, Shiddik MAB, Chowdhury AH. “Spatiotemporal patterns of climate-sensitive vector-borne diseases in Bangladesh: leveraging machine learning and spatial regression for intervention strategies.” BMC medicine (2026). PMID: 41975424 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [31]
Barrow A, Barrow S, Bah Y. “Integrated housing quality and insecticide-treated net use: propensity score methods for childhood anemia prevention in The Gambia.” Malaria journal (2026). PMID: 41975408 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [32]
Rios-Teran CA, Tiedje KE, Bangre O et al.. “The dynamics of asymptomatic Plasmodium spp. infections following 10 years of malaria control interventions in Northern Sahelian Ghana.” PLoS neglected tropical diseases (2026). PMID: 41973755 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup, Prevention and Screening - [33]
Smith SR, Nakibuuka V, Frick KD et al.. “Oxygen blenders for prevention of retinopathy of prematurity are highly cost-effective in Uganda.” Frontiers in medicine (2026). PMID: 41970396 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [34]
Zafindraibe NJ, Razafindrakoto AC, Zemey CB et al.. “Prevalence of malaria during pregnancy and coverage of intermittent preventive treatment with sulfadoxine-pyrimethamine in urban Amboasary-Sud, Southern Madagascar.” Malaria journal (2026). PMID: 41965694 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup - [35]
Addis GT, Addis MT, Mihret Y et al.. “"Referral patterns and associated factors among adult patients admitted with Severe Malaria at Shedeho Meket Primary Hospital, Northeast Ethiopia".” BMC infectious diseases (2026). PMID: 41963834 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Clinical Features and Variants - [36]
Jaramillo-Underwood A, Ogunniyi A, Zhou H et al.. “Risk factors and geospatial associations with Plasmodium falciparum malaria infection and IgG seroprevalence: Nigeria, 2018.” The Journal of infectious diseases (2026). PMID: 41960779 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [37]
Matamanda SH, Musakwa W, Dzomba A. “Malaria at the margins: climatic extremes, migration, and urban informal settlement risk in South Africa.” Malaria journal (2026). PMID: 41952191 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [38]
Ilunga J, Mulenga-Cilundika P, Ekofo J et al.. “Barriers to integration of passive screening for sleeping sickness in Bibanga Health District, Democratic Republic of the Congo.” PLoS neglected tropical diseases (2026). PMID: 41950271 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [39]
Nguyen-Tien T, Tran V, Nguyen TM et al.. “Malaria situation in a highly endemic province in the Central Highlands of Vietnam: a retrospective analysis.” Malaria journal (2026). PMID: 41947165 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [40]
Sekitoleko I, Komata R, Ssali I et al.. “Early-life infectious and nutritional exposures and cardiovascular risk in early adulthood in Uganda: protocol for a new round of data collection in the Entebbe Mother and Baby Study birth cohort at 21 years (EMaBS@21).” BMJ open (2026). PMID: 41946545 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [41]
Belay A, Semahegn A, Hailu BT et al.. “Integration of population-based surveys for neglected tropical diseases: A scoping review.” PLoS neglected tropical diseases (2026). PMID: 41941535 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors - [42]
Wynkoop HJ, Lintner-Rivera M, Taylor T et al.. “Malarial pneumonopathy in Malawian children with cerebral malaria.” Malaria journal (2026). PMID: 41935286 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Clinical Features and Variants - [43]
Monteiro GM, Aïkpon RY, Dandonougbo C et al.. “Identification of malaria hotspots in southwestern Benin through spatial joint modelling of malaria incidence and vector abundance.” Malaria journal (2026). PMID: 41935258 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [44]
Tadesse S, Korma W, Sherfa A et al.. “Fatal and non-fatal health outcomes of malaria among reproductive age women in Eastern Sub-Saharan Africa, from 1990 to 2023.” Malaria journal (2026). PMID: 41933334 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [45]
Bennett A, Cotter C, Zarlinda I et al.. “Adapting reactive case detection strategies for high-risk populations to increase malaria infection detection in Aceh Province, Indonesia.” PLOS global public health (2026). PMID: 41931566 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup - [46]
Odibo EO, Nmorsi OPG, Egwunyenga OA et al.. “Haematological responses in children under 5 years with malaria and soil-transmitted helminth coinfections in Delta State, Nigeria: a cross-sectional study.” Therapeutic advances in infectious disease (2026). PMID: 41929652 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [47]
Tsigie M, Baldor L, Feufack-Donfack LB et al.. “Genetic variation in the Duffy blood group among vivax malaria patients and its impact on disease susceptibility.” Malaria journal (2026). PMID: 41928206 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [48]
Yitageasu G, Demoze L. “Spatial epidemiology of malaria by bed net utilization in 19 sub-Saharan African countries: a DHS-based study (2013-2023).” Malaria journal (2026). PMID: 41923227 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [49]
Ladan SM, Lima NP, Orimadegun AE et al.. “Prevalence and inequalities of missed opportunities for intermittent preventive therapy (IPTp) of malaria among pregnant women: an analysis of 2018 Nigeria DHS.” Malaria journal (2026). PMID: 41918116 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [50]
Odongo W, Seffren V, Obiet K et al.. “Community health volunteers improve access to malaria case management in Siaya County, Kenya.” Malaria journal (2026). PMID: 41917974 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup - [51]
Stephenson KB, Greenfeld A, Ryan MG et al.. “Egg supplementation for 24 weeks does not improve linear growth or reduce small intestinal permeability in Sierra Leonean children with moderate wasting: a randomized, blinded, controlled trial.” The American journal of clinical nutrition (2025). PMID: 41193034 ↗
L1bRCTCited in: History and Physical Examination - [52]
Sié A, Ouattara M, Bountogo M et al.. “Mass Azithromycin Distribution and Cause-Specific Mortality among Children Ages 1-59 Months Old: A Secondary Analysis of a Cluster-Randomized Controlled Trial.” The American journal of tropical medicine and hygiene (2026). PMID: 41252743 ↗
L1bRCTCited in: History and Physical Examination - [53]
Saady M, Ewaisha R, Azzazy HME. “Regional burden of undifferentiated fever and leading infectious etiologies of acute febrile illness in low- and middle-income countries: a meta-analysis.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2025). PMID: 41161530 ↗
L2aSR_OBSCited in: History and Physical Examination - [54]
Chitrapady S, Rajendran R, K H et al.. “Machine-learning-based artificial intelligence tools for the diagnosis of tropical fevers: a systematic review and meta-analysis protocol of diagnostic test accuracy.” BMJ open (2025). PMID: 40854843 ↗
L2aSR_OBSCited in: History and Physical Examination - [55]
Anselmo A, D'Ugo E, Corrent L et al.. “A case of Human Pegivirus acute febrile infection diagnosed by Next Generation Sequencing (NGS).” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 41638349 ↗
L4CASE_REPORTCited in: History and Physical Examination - [56]
Sous M, Boti M, Mose B et al.. “Reversible paralysis in pregnancy, thinking beyond malaria: a case report.” BMC infectious diseases (2025). PMID: 41286642 ↗
L4CASE_REPORTCited in: History and Physical Examination - [57]
Srirama S, Sihag KK, Chandrasekaran AK et al.. “Acute undifferentiated febrile illness in a traveler returning from Burkina Faso, West Africa to Puducherry, India- a case report.” BMC infectious diseases (2025). PMID: 40646441 ↗
L4CASE_REPORTCited in: History and Physical Examination - [58]
Batra P, Kaushik D, Rasane P et al.. “Early-Life Protein Nutrition and Enzymatic Regulation: Mechanistic Pathways Linking Growth Faltering, Stunting, and Obesity.” FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2026). PMID: 41933918 ↗
L5REVIEW_NARRATIVECited in: History and Physical Examination - [59]
Abraham P, Lubis IND, Novivanti R et al.. “The household economic burden of human-only and zoonotic malaria, compared to other causes of acute febrile illness in Indonesia.” BMJ global health (2026). PMID: 41887663 ↗
L5OTHERCited in: History and Physical Examination, Diagnosis and Workup - [60]
Sambe BS, Diagne A, Diatta AS et al.. “Malaria misdiagnosis among febrile patients in Senegal: implications for the underestimation of Plasmodium species diversity and malaria burden.” Malaria journal (2026). PMID: 41794727 ↗
L5OTHERCited in: History and Physical Examination - [61]
Moutombi Ditombi BC, Fritz M, Kombila Koumavor CA et al.. “Molecular evidence of co-circulation of different dengue virus serotypes associated with malaria co-infection among febrile children in Libreville, Gabon.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 41722758 ↗
L5OTHERCited in: History and Physical Examination - [62]
Lo TQ, Edu-Quansah EP, Dogba J et al.. “Acute febrile illness surveillance using TaqMan Array Cards in two urban health facilities, Monrovia, Liberia, December 2018-March 2020.” PLoS neglected tropical diseases (2026). PMID: 41662363 ↗
L5OTHERCited in: History and Physical Examination - [63]
Arsuaga M, Oliveira-Souto I, Sánchez-Montalvá A et al.. “Travel health risks in adults over 60 years of age: insights from the +Redivi network in Spain.” Journal of travel medicine (2026). PMID: 41614979 ↗
L5OTHERCited in: History and Physical Examination - [64]
Merritt C, Vincenz C, Dolo Z et al.. “Association between placental malaria, postnatal linear growth, and body mass index in the Dogon Longitudinal Study, Mali.” Malaria journal (2026). PMID: 41501807 ↗
L5OTHERCited in: History and Physical Examination - [65]
Chitrapady S, Rajendran R, Haritha K et al.. “Development and evaluation of a diagnostic aiding tool for differentiating tropical fevers using artificial intelligence approach: a study protocol from tertiary care hospital in South India.” BMJ open (2026). PMID: 41490850 ↗
L5OTHERCited in: History and Physical Examination - [66]
Legesse F, Berhane N. “Prevalence of malaria and diagnostic performance of malaria rapid diagnostic tests compared to microscopy among febrile patients at Pawe General Hospital, Northwest Ethiopia.” BMC infectious diseases (2025). PMID: 41449340 ↗
L5OTHERCited in: History and Physical Examination - [67]
Remppis J, Weitz R, Aasi M et al.. “Child health in international travel: A German airport survey.” Travel medicine and infectious disease (2026). PMID: 41386402 ↗
L5OTHERCited in: History and Physical Examination - [68]
Lambebo IH, Eba K, Tucho GT. “Association between climatic conditions and infectious diseases: implications for Central Ethiopia region.” BMC infectious diseases (2025). PMID: 41331557 ↗
L5OTHERCited in: History and Physical Examination - [69]
Hedible KGB, Sawadogo AG, Zair Z et al.. “Care management and determinants of day 14 mortality in severely ill children aged under 5 years subsequent to hypoxaemia diagnosed using routine pulse oximetry in primary care: evidence from the AIRE project.” BMJ global health (2025). PMID: 41309154 ↗
L5OTHERCited in: History and Physical Examination - [70]
Tariq H, Alamgir A, Punar Z et al.. “Climate variability and infectious disease burden in Coastal Sindh, Pakistan: A trend analysis (2019-2022).” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 41285193 ↗
L5OTHERCited in: History and Physical Examination - [71]
Kim JH, Chebu P, Fayomade R et al.. “Multi-Pathogen Surveillance of Acute Febrile Illness in Nigeria Using TaqMan Array Cards: Implementation Successes and Lessons Learned From the SAFIAN Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 41263690 ↗
L5OTHERCited in: History and Physical Examination - [72]
Quiner CA, Ephraim AZ, Kwaghe V et al.. “Epidemiology of Plasmodium spp. Detection Among Acute Febrile Illness Patients in Two Regions of Nigeria.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 41263689 ↗
L5OTHERCited in: History and Physical Examination - [73]
Erameh C, Courtney LP, Kwaghe V et al.. “High Burden of Coinfections With Epidemic-Prone Pathogens Among Febrile Patients in Nigeria: A Multi-Pathogen Surveillance Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 41263686 ↗
L5OTHERCited in: History and Physical Examination - [74]
Hedrich N, Lovey T, Bernhard J et al.. “Real-time illness monitoring in travellers: an international, prospective, digital surveillance study.” Travel medicine and infectious disease (2025). PMID: 41260318 ↗
L5OTHERCited in: History and Physical Examination - [75]
Tiberti N, Bertoli G, Mazzi C et al.. “Profiling of circulating immune factors and host-derived extracellular vesicles in response to bacterial or malaria acute fever.” Infection (2026). PMID: 41258581 ↗
L5OTHERCited in: History and Physical Examination - [76]
Abubakr M, Mohamed NS, Sami H et al.. “Epidemiological trends of malaria in Sennar State, Sudan.” Malaria journal (2025). PMID: 41214714 ↗
L5OTHERCited in: History and Physical Examination - [77]
Kaba S, Diallo MDD, Winner MBF. “Influence of community norms on caregivers' early care-seeking behaviour for under-5 children with fever in Guinea, a secondary analysis study.” Malaria journal (2025). PMID: 41084008 ↗
L5OTHERCited in: History and Physical Examination - [78]
Colubri A, Willing N, Grozdani A et al.. “Travel Healthy, a mobile app for participatory surveillance among U.S. international travelers.” Travel medicine and infectious disease (2025). PMID: 41083032 ↗
L5OTHERCited in: History and Physical Examination - [79]
Akanbi DO, Abaye BB, Averhoff F et al.. “Detection of dengue, malaria, and additional causes of acute febrile illness: The need for expanded testing, Bayelsa State, Nigeria.” PLoS neglected tropical diseases (2025). PMID: 41071829 ↗
L5OTHERCited in: History and Physical Examination - [80]
Amoadu M, Alhassan A, Odoom E. “Delay in malaria care-seeking for children under five in Africa: a systematic review.” Malaria journal (2026). PMID: 41845404 ↗
L2aSR_OBSCited in: Clinical Features and Variants - [81]
Meena P, Singla V, Deshpande A et al.. “Clinical characteristics and outcome of malaria-associated acute kidney injury in adult patients: a systematic review and meta analysis.” Malaria journal (2026). PMID: 41620769 ↗
L2aSR_OBSCited in: Clinical Features and Variants - [82]
Okek EJ, Jehopio J, Sande OJ et al.. “Progression from uncomplicated to severe malaria among children in settings receiving different combinations of malaria control interventions in sub-Saharan Africa: a systematic review and meta-analysis.” Tropical medicine and health (2026). PMID: 41862968 ↗
L2aSR_OBSCited in: Clinical Features and Variants - [83]
Riggle BA, Chamzas A, Gopalakrishnan M et al.. “Safety, tolerability, and pharmacokinetics of 6-diazo-5-oxo-L-norleucine (DON) in Malawian adults with and without malaria: a Phase I dose-escalation clinical trial.” The Journal of infectious diseases (2026). PMID: 41748157 ↗
L2bTRIAL_NONRANDOMCited in: Clinical Features and Variants - [84]
Animut A, Bekana T, Siraj SZ et al.. “Treatment outcome and associated factors of severe malaria among admitted children in the Gambella Region, Southwest Ethiopia: a retrospective study design.” Malaria journal (2026). PMID: 41808107 ↗
L2bCOHORTCited in: Clinical Features and Variants, Diagnosis and Workup, Management - [85]
Noor M, Junaid M, Furqan A. “Burden of Plasmodium vivax and Plasmodium falciparum Malaria: clinical insights from a prospective study in Jacobabad, Sindh, Pakistan.” Malaria journal (2026). PMID: 41680751 ↗
L2bCOHORTCited in: Clinical Features and Variants - [86]
Scherer N, Nemerimana M, Nanyunja C et al.. “Early childhood intervention for children at risk of developmental disabilities and their caregivers in Rwanda: study protocol for the PDC/Baby Ubuntu cluster randomised trial.” Trials (2026). PMID: 41862972 ↗
L2bTRIAL_NONRANDOMCited in: Clinical Features and Variants, Diagnosis and Workup, Supportive Care and Complication Management - [87]
Wakai T, Chinedu S, Afolabi I. “Heme oxygenase-1 and malaria pathogenesis.” Frontiers in immunology (2026). PMID: 41836435 ↗
L5REVIEW_NARRATIVECited in: Clinical Features and Variants - [88]
Toure M, Keita S, Keita B et al.. “Trends in malaria indicators in urban and peri-urban areas of Bamako: a scoping review protocol.” Systematic reviews (2026). PMID: 41736077 ↗
L5REVIEW_NARRATIVECited in: Clinical Features and Variants - [89]
Cardona F, Héritier L, Cortaredona S et al.. “Assessment of Long-Term Sequelae After Severe Malaria: A Retrospective Study.” Pathogens (Basel, Switzerland) (2026). PMID: 41754407 ↗
L2bCOHORTCited in: Clinical Features and Variants, Management - [90]
Okullo AE, Ouma S, John CC et al.. “Prevalence and risk factors of gross neurologic deficits in children after severe malaria: A systematic review and meta-analysis.” PloS one (2026). PMID: 41843569 ↗
L2aSR_OBSCited in: Clinical Features and Variants - [91]
Qi YP, Crider KS, Gutman J et al.. “Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.” The Cochrane database of systematic reviews (2026). PMID: 41705996 ↗
L2aSR_OBSCited in: Clinical Features and Variants, Prevention and Screening - [92]
Sastre-Martínez AD, Gutiérrez MAG, Vallejo-Serna RA et al.. “Cerebral malaria caused by Plasmodium vivax in an afrodescendant adult in Colombia: case report.” Malaria journal (2026). PMID: 41851764 ↗
L4CASE_REPORTCited in: Clinical Features and Variants, Management, Supportive Care and Complication Management - [93]
Olwit G, Gutanamuka TB, Chris-Uchendu HC et al.. “Malaria-Associated Acute Kidney Injury: A Key Driver of Mortality in Endemic Regions.” International journal of nephrology and renovascular disease (2026). PMID: 41938719 ↗
L5REVIEW_NARRATIVECited in: Clinical Features and Variants - [94]
Nuin NA, Rajahram GS, Barber BE et al.. “G6PD variants but not Filipino beta-thalassemia are associated with reduced risk of Plasmodium knowlesi infection in Sabah, Malaysia.” Malaria journal (2026). PMID: 41987254 ↗
L5OTHERCited in: Clinical Features and Variants, Diagnosis and Workup - [95]
Lenz T, Sirel M, Hoppe H et al.. “Epigenetics and chromatin structure regulate var2csa expression and the placental-binding phenotype in Plasmodium falciparum.” eLife (2026). PMID: 41984626 ↗
L5OTHERCited in: Clinical Features and Variants - [96]
Klein SG, Mota KCP, Borges BC et al.. “Anti-GPI scFv as a Promising Tool for Intervention Against Cerebral Malaria in Mice.” International journal of molecular sciences (2026). PMID: 41977140 ↗
L5OTHERCited in: Clinical Features and Variants - [97]
Ravishankar K, Mace KE, Koiso S et al.. “Mapping Hospitals That Treat Severe Malaria Cases in the United States: Evidence to Inform Health Systems Strategies for Intravenous Artesunate Supply.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 41955078 ↗
L5OTHERCited in: Clinical Features and Variants - [98]
Caiazzo R, Panero B, Carello M et al.. “Pediatric malaria in a non-endemic European setting: clinical patterns, laboratory markers, and the ambiguous role of immunity.” Infection (2026). PMID: 41935227 ↗
L5OTHERCited in: Clinical Features and Variants, Management - [99]
Kasprowicz D, Korzeniewski K, Wilczyńska W. “Clinical Characteristics and Outcomes of Hospitalized Malaria Patients in Rural Madagascar.” Journal of clinical medicine (2026). PMID: 41899312 ↗
L5OTHERCited in: Clinical Features and Variants, Supportive Care and Complication Management - [100]
Bendezu J, Larrauri-Aguilar P, Bautista R et al.. “Phenotypic and genotypic characterization of Plasmodium falciparum field isolates lacking pfhrp2 gene.” Malaria journal (2026). PMID: 41840576 ↗
L5OTHERCited in: Clinical Features and Variants - [101]
Figueroa-Downing D, Kelly SL, Cavelan A et al.. “Timing of the fourth dose of RTS,S/AS01 malaria vaccine in perennial settings: a modelling study.” Malaria journal (2026). PMID: 41827013 ↗
L5OTHERCited in: Clinical Features and Variants - [102]
Chelangat SC, Nakawuki A, Orech S et al.. “Facilitators and barriers to adherence to severe malaria treatment guidelines in children at Mbale Regional Referral Hospital, Uganda: a health workers' perspective.” Malaria journal (2026). PMID: 41749217 ↗
L5OTHERCited in: Clinical Features and Variants - [103]
Diffendall G, Millot P, Chen P et al.. “Longitudinal plasma metabolomics reveals a role for taurine in asymptomatic malaria and seasonal persistence.” Nature microbiology (2026). PMID: 41708949 ↗
L5OTHERCited in: Clinical Features and Variants - [104]
Boopathi PA, Singh S, Roy P et al.. “Comparative clinical transcriptome of pir genes in severe Plasmodium vivax malaria.” PLoS neglected tropical diseases (2026). PMID: 41706749 ↗
L5OTHERCited in: Clinical Features and Variants - [105]
Kanyamukenge DB, Maseko T, Khote FL et al.. “Young children with severe malaria in the Kapolowe health zone: an analysis of their parents' health-seeking behaviors and the challenges they face.” Malaria journal (2026). PMID: 41680770 ↗
L5OTHERCited in: Clinical Features and Variants - [106]
Unnikrishnan G, Singh A. “Diagnostic Accuracy of Point-of-Care Devices for Glucose-6-Phosphate Dehydrogenase Deficiency Detection Among Malaria Patients: A Systematic Review and Meta-Analysis.” Tropical medicine & international health : TM & IH (2026). PMID: 41774916 ↗
L2aSR_OBSCited in: Diagnosis and Workup - [107]
Zambo Bitye BM, Mbianda Nana CM, Kwanou Tchakounte BD et al.. “cTfh Cell Activation and Changes in BTLA and LAG-3 Expression Differentially Associate With Poor Pregnancy Outcome in Plasmodium falciparum Placental Malaria.” Journal of immunology research (2026). PMID: 41983955 ↗
L5OTHERCited in: Diagnosis and Workup - [108]
Pavesi A, Ciccarone A, Logiudice J et al.. “Blood Smear Examination Matters: an Incidental Case of Tick-Borne Relapsing Fever in a Traveller Returning from Senegal.” Travel medicine and infectious disease (2026). PMID: 41974313 ↗
L5OTHERCited in: Diagnosis and Workup - [109]
Chen W, Ochomo E, Muok E et al.. “Modeling and Laboratory Experiments to Assess Detection of Plasmodium falciparum in Wastewater: Insights for Wastewater-Based Surveillance of Malaria.” Environmental science & technology (2026). PMID: 41964709 ↗
L5OTHERCited in: Diagnosis and Workup - [110]
Cavros I, Abanyie F, Kamara ARY et al.. “Efficacy and safety of artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ) for the treatment of uncomplicated Plasmodium falciparum malaria among children 6-59 months in three sentinel sites of Sierra Leone, 2021-2022.” Malaria journal (2026). PMID: 41957831 ↗
L5OTHERCited in: Diagnosis and Workup - [111]
Valkiūnas G, Iezhova TA, Chagas CRF et al.. “New experimental insights into the biology of avian malaria parasites.” Malaria journal (2026). PMID: 41952185 ↗
L5OTHERCited in: Diagnosis and Workup - [112]
Adeogun AO, Adetunji O, Babalola AS et al.. “Spatial eco-climatic gradients drive adaptive 2La chromosomal inversion polymorphism in Anopheles coluzzii, a major malaria vector in Nigeria.” International journal of health geographics (2026). PMID: 41943093 ↗
L5OTHERCited in: Diagnosis and Workup - [113]
Cuamba I, Santano R, Grau-Pujol B et al.. “Helminth coinfections mitigate clinical, parasitological, and immune outcomes in Mozambican children with malaria.” BMC medicine (2026). PMID: 41918093 ↗
L5OTHERCited in: Diagnosis and Workup - [114]
Shaba-Santu A, Moonga L, Ogata S et al.. “Prevalence and factors associated with malaria amongst under-five children in Senga Hill District, Northern Province, Zambia, a community-based cross-sectional study.” Malaria journal (2026). PMID: 41917959 ↗
L5OTHERCited in: Diagnosis and Workup - [115]
Maulana T, Marthoenis M, Almira CS et al.. “Socio-demographic characteristics and parasite density patterns of Plasmodium knowlesi Malaria in Aceh, Indonesia: insights from hospital-based data.” Infection (2026). PMID: 41913029 ↗
L5OTHERCited in: Diagnosis and Workup - [116]
Ahogni I, Avanon H, Hueha C et al.. “The accuracy of recording malaria rapid diagnostic test (RDT) results in public health facilities in Benin; results from the MaCRA project.” Malaria journal (2026). PMID: 41904563 ↗
L5OTHERCited in: Diagnosis and Workup - [117]
Jima B, Wondale B, Eligo N et al.. “Microscopy underestimates submicroscopic malaria infections in Ethiopia's southern rift valley: a community-based cross-sectional study.” Malaria journal (2026). PMID: 41904559 ↗
L5OTHERCited in: Diagnosis and Workup - [118]
Li F, Xu O, Zhou J et al.. “Functional characterization of AsOBP21f, an odorant-binding protein involved in human odor detection in the malaria vector Anopheles sinensis.” Parasites & vectors (2026). PMID: 41872964 ↗
L5OTHERCited in: Diagnosis and Workup - [119]
Carey-Ewend K, Shepard H, Yang G et al.. “Frequent Plasmodium ovale recurrence in coastal Tanzania.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 41862423 ↗
L5OTHERCited in: Diagnosis and Workup - [120]
Matulis GA, Smith HP, Hall G et al.. “Characterization of arbovirus infections in patients within Haiti by screening discarded malaria rapid diagnostic test cassettes.” PLoS neglected tropical diseases (2026). PMID: 41860982 ↗
L5OTHERCited in: Diagnosis and Workup - [121]
Boadu S, Axame WK, Abanga WA et al.. “Evaluation of malaria rapid diagnostic test kit performance in a high-transmission setting: a facility-based cross-sectional study in rural Ghana.” Malaria journal (2026). PMID: 41857588 ↗
L5OTHERCited in: Diagnosis and Workup - [122]
Pippione AC, Villella N, Fornaseri F et al.. “Structure-based design of new pyrazole inhibitors targeting Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH).” European journal of medicinal chemistry (2026). PMID: 41855879 ↗
L5OTHERCited in: Diagnosis and Workup, Management, Prevention and Screening - [123]
Fenomanana J, Ravoavy A, Rakotoarisoa M et al.. “Field and laboratory evaluation of Abbott-Bioline™ Malaria Ag Pf/Pv RDT performance in a high-transmission setting: contrasting results with a low-endemic area.” Malaria journal (2026). PMID: 41851713 ↗
L5OTHERCited in: Diagnosis and Workup - [124]
Sarma K, Sarma H, Deka J. “Advancing global malaria control: therapeutic strategies, drug discovery, and formulation innovations.” Infection (2026). PMID: 41851575 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup - [125]
Duncombe CJ, Poehlman AS, Conrad EN et al.. “Host biological sex directs immune control of the Plasmodium parasite liver stage in mice.” Frontiers in immunology (2026). PMID: 41846936 ↗
L5OTHERCited in: Diagnosis and Workup - [126]
Mmweteni RE, Philbert AB, Mkandawile G et al.. “Detection of supergroup B Wolbachia strains and their co-infection with Plasmodium falciparum in wild Anopheles funestus in southeastern Tanzania: implications for malaria control.” Parasites & vectors (2026). PMID: 41845520 ↗
L5OTHERCited in: Diagnosis and Workup - [127]
Pfaffendorf C, Dejon-Agobé JC, Edoa JR et al.. “Population pharmacokinetics of fosmidomycin and clindamycin in combination with artesunate for uncomplicated Plasmodium falciparum malaria in Gabonese children and adults.” Malaria journal (2026). PMID: 41857641 ↗
L1bRCTCited in: Management - [128]
Xie K, Otuko R, Marathe A et al.. “Cost and cost-effectiveness of ivermectin mass drug administration for malaria control in Kwale county, Kenya: a modelling analysis of a cluster-randomised trial.” The Lancet. Global health (2026). PMID: 41713445 ↗
L1bRCTCited in: Management, Prevention and Screening - [129]
Ubalde J, Bradshaw C, Fatima SH et al.. “Systematic review of climate change interventions for improving child health.” BMJ paediatrics open (2026). PMID: 41856671 ↗
L2aSR_OBSCited in: Management - [130]
Habarugira F, Batamuriza J, Ndahimana R et al.. “The Global Landscape of Plasmodium falciparum Drug Resistance Markers, 2005-2025: A Systematic Review and Meta-Analysis.” Pathogens (Basel, Switzerland) (2026). PMID: 41754431 ↗
L2aSR_OBSCited in: Management - [131]
Bundi CK, Muñoz O, Kibwana E et al.. “B and T cell responses to pre-erythrocytic R21/Matrix-M and blood-stage RH5.1/Matrix-M malaria vaccines in endemic settings.” Frontiers in immunology (2026). PMID: 41846927 ↗
L2bTRIAL_NONRANDOMCited in: Management, Prevention and Screening - [132]
Zhang X, Milligan P, Cheung YB. “Flexible and Interpretable Modeling of Overlapping Exposure Risks in Self-Controlled Case Series Analysis.” Statistics in medicine (2026). PMID: 41979390 ↗
L4CASE_REPORTCited in: Management, Prevention and Screening - [133]
Moriarty LF, Betoulle MM, Troell P et al.. “Antimalarial efficacy monitoring after nearly 20 years of artemisinin-based combination therapy in Africa: recalibrating guidance.” Trends in parasitology (2026). PMID: 41933996 ↗
L5REVIEW_NARRATIVECited in: Management - [134]
Niyomwungere D, Sinarinzi P, Caspar E et al.. “Border Region Surveillance of Malaria Drug Resistance, Northern Burundi, 2023-2024.” Emerging infectious diseases (2026). PMID: 41927306 ↗
L5OTHERCited in: Management - [135]
Ariefta NR, Beteck RM, Legoabe LJ et al.. “Synthetic quinolone-tethered aminoguanidine derivatives exhibit potent antiplasmodial activity.” International journal of antimicrobial agents (2026). PMID: 41921671 ↗
L5OTHERCited in: Management - [136]
Opperman D, Rabie T, Maré M et al.. “Protein Arginine Methyltransferase Inhibitors Target Multiple Stages of Plasmodium falciparum Parasites In Vitro.” ACS infectious diseases (2026). PMID: 41914674 ↗
L5OTHERCited in: Management - [137]
Wu L, Vllasaliu D, Mabayoje DA et al.. “Nanoscaffold-based 3D human liver spheroids for predictive hepatotoxicity screening of antimalarial compounds from the global health priority box.” Parasites & vectors (2026). PMID: 41872940 ↗
L5OTHERCited in: Management - [138]
Rosenthal M, Goldberg DE. “4-Aminoquinolines block heme iron reactivity and interfere with artemisinin action.” eLife (2026). PMID: 41870038 ↗
L5OTHERCited in: Management - [139]
Morgan CJ, Scoullar MJL, Melepia PU et al.. “Women's perspectives on health service integration for multi-morbidity in pregnancy, childbirth, and postpartum in a high-burden setting.” Med (New York, N.Y.) (2026). PMID: 41861824 ↗
L5OTHERCited in: Management - [140]
Aamir M, Rezaee K, Anari MS. “Intelligent in-silico prioritization of antimalarial peptide candidates under explicit physicochemical windows via de novo CTCM-Neo generation and conformal-gated calibrated classification.” Frontiers in cellular and infection microbiology (2026). PMID: 41859462 ↗
L5OTHERCited in: Management - [141]
Khilari A, Sharma S, Bajpai M et al.. “Targeted Genomic Surveillance Unveils Genetic Variations Linked to Regional Malaria Drug Resistance Dynamics in India.” Open forum infectious diseases (2026). PMID: 41846600 ↗
L5OTHERCited in: Management - [142]
Milić M, Obi P, Vanderwal CD et al.. “Polypharmacology in malaria treatment: single drugs, multiple mechanisms, greater impact.” Trends in parasitology (2026). PMID: 41846229 ↗
L5REVIEW_NARRATIVECited in: Management - [143]
Gonçalves AF, Lima-Pinheiro A, Sampaio-Marques B et al.. “Profiling 26S Proteasome Activity of Plasmodium falciparum Monitored by a Live-Cell Assay.” International journal of molecular sciences (2026). PMID: 41828333 ↗
L5OTHERCited in: Management - [144]
Salazar YEAR, Rezende AM, Puça MCSB et al.. “Emergence of artemisinin-based combination therapy resistance markers in Plasmodium falciparum from the Brazilian tri-border region of the Guiana Shield.” Antimicrobial agents and chemotherapy (2026). PMID: 41817181 ↗
L5OTHERCited in: Management - [145]
Moritz A, Hirn-Derksen B, Klein S et al.. “Integrative preclinical strategy for pharmacokinetic profiling and candidate selection of 3-hydroxypropanamidines: a promising antimalarial class.” Malaria journal (2026). PMID: 41808149 ↗
L5OTHERCited in: Management - [146]
Putaporntip C, Somkuna J, Rojrung R et al.. “Contrasting evolutionary trajectories of pyrimethamine resistance in human and zoonotic malaria parasites.” Malaria journal (2026). PMID: 41808095 ↗
L5OTHERCited in: Management - [147]
Vandy A, Turay BA, Lahai M et al.. “Herbal product use in urban slum communities of Freetown, Sierra Leone: Consumption patterns, predictors, and ethnomedicinal applications.” Journal of ethnobiology and ethnomedicine (2026). PMID: 41794856 ↗
L5OTHERCited in: Management - [148]
Abadia ACM, Diedrich D, Vieira LC et al.. “In Vivo Antimalarial Activity and Toxicological Profile of LAFIS10, a Piperazine Derivative From Ursolic Acid.” Tropical medicine & international health : TM & IH (2026). PMID: 41788057 ↗
L5OTHERCited in: Management - [149]
Alemayehu G, Awoke A, Kassa Z. “Ethnobotanical documentation and conservation assessment of medicinal plants used by the Somali community in Karamara forest patches, Eastern Ethiopia.” Journal of ethnobiology and ethnomedicine (2026). PMID: 41787442 ↗
L5OTHERCited in: Management - [150]
Garg RK, Pandey S, Mahdi RA et al.. “Spectrum of movement disorders in Malaria: a systematic review of case reports, case series, and cohort studies.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2025). PMID: 40537708 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [151]
Sankar J, Das RR, Banothu KK. “Fluid resuscitation in children with severe infection and septic shock: a systematic review and meta-analysis.” European journal of pediatrics (2024). PMID: 38916738 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [152]
Casey RM, Najjengo MS, Lubega I et al.. “Adverse events following immunization (AEFI) with fractional one-fifth and one-half doses of yellow fever vaccine compared to full dose in children 9-23 months old in Uganda, 2019-2020 - Preliminary report.” Vaccine (2024). PMID: 39153293 ↗
L1bRCTCited in: Supportive Care and Complication Management - [153]
Birbeck GL, Seydel KB, Mwanza S et al.. “Acetaminophen and Ibuprofen in Pediatric Central Nervous System Malaria: A Randomized Clinical Trial.” JAMA neurology (2024). PMID: 38857015 ↗
L1bRCTCited in: Supportive Care and Complication Management - [154]
Taylor SM, Korwa S, Wu A et al.. “Monthly sulfadoxine/pyrimethamine-amodiaquine or dihydroartemisinin-piperaquine as malaria chemoprevention in young Kenyan children with sickle cell anemia: A randomized controlled trial.” PLoS medicine (2022). PMID: 36215323 ↗
L1bRCTCited in: Supportive Care and Complication Management - [155]
Haine V, Oneko M, Debois M et al.. “Safety of RTS,S/AS01E malaria vaccine up to 1 year after the third dose in Ghana, Kenya, and Malawi (EPI-MAL-003): a phase 4 cohort event monitoring study.” The Lancet. Global health (2025). PMID: 40288377 ↗
L2bTRIAL_NONRANDOMCited in: Supportive Care and Complication Management - [156]
Tembo D, Mwanza S, Mwaba C et al.. “Risk factors for acute kidney injury at presentation among children with CNS malaria: a case control study.” Malaria journal (2022). PMID: 36316704 ↗
L2bTRIAL_NONRANDOMCited in: Supportive Care and Complication Management - [157]
Ray STJ, Fuller CE, Ahmadu A et al.. “Aetiologies, neuroradiological features, and risk factors for mortality and long-term neurosequelae of febrile coma in Malawian children: a prospective cohort study.” The Lancet. Global health (2025). PMID: 40280145 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [158]
Opoka RO, Namazzi R, Datta D et al.. “Severe falciparum malaria in young children is associated with an increased risk of post-discharge hospitalization: a prospective cohort study.” Malaria journal (2024). PMID: 39633351 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [159]
Ranjbar M, Katureebe C, Musanhu CC et al.. “The 24, 2 hours initiative: a game changer in malaria mortality reduction.” Malaria journal (2025). PMID: 41219920 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [160]
Vathi S, Corriero A, Rodríguez EE et al.. “Management and monitoring strategies for severe cerebral malaria: a guide for the intensivist.” Annals of intensive care (2025). PMID: 41060528 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [161]
Aderinto N, Abraham IC, Olatunji G et al.. “Stroke incidence, presentation, and outcomes in malaria: a review of current evidence.” Malaria journal (2025). PMID: 40533728 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [162]
Long B, MacDonald A, Liang SY et al.. “Malaria: A focused review for the emergency medicine clinician.” The American journal of emergency medicine (2024). PMID: 38096639 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [163]
Tolou-Ghamari Z. “A Review of the Association between Infections, Seizures, and Drugs.” Central nervous system agents in medicinal chemistry (2025). PMID: 38676494 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [164]
Deng S, Wang W, Lu W et al.. “Anti-NMDAR encephalitis following malaria: expanding the spectrum of post-malarial neurological syndromes.” Frontiers in immunology (2026). PMID: 41909705 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [165]
Kumar A, Agatrao BA, Prakash A et al.. “Malaria-associated splenic haemorrhage requiring emergency splenectomy: a rare complication managed in a resource-constrained setting.” Malaria journal (2026). PMID: 41787355 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [166]
Nayak B, Mohanty S, Das S et al.. “Radiological findings in fulminant cerebral malaria: a rare neuroimaging presentation.” Malaria journal (2025). PMID: 41423666 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [167]
Huang XA, Xiang R, Liao RH et al.. “Babesia microti (Babesiidae, Piroplasmida) infection in a Chinese traveler returning from the United States of America.” Infectious diseases of poverty (2025). PMID: 40490844 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [168]
Wu X, Qin N, Yi F et al.. “Cerebral malaria presenting as nonconvulsive status epilepticus: a case report.” Malaria journal (2024). PMID: 38500090 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [169]
Postels DG, Katangwe-Chirwa T. “Cerebral malaria.” Seminars in pediatric neurology (2025). PMID: 40701686 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [170]
Comino Garcia-Munoz A, Varlet I, Grau GE et al.. “Contribution of Magnetic Resonance Imaging Studies to the Understanding of Cerebral Malaria Pathogenesis.” Pathogens (Basel, Switzerland) (2024). PMID: 39770302 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [171]
Akafity G, Kumi N, Ashong J. “Diagnosis and management of malaria in the intensive care unit.” Journal of intensive medicine (2024). PMID: 38263976 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [172]
Toudou-Daouda M. “Epilepsy in Niger: An overview of the current situation.” Epilepsia open (2023). PMID: 37042866 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [173]
Yacubian EMT, Kakooza-Mwesige A, Singh G et al.. “Common infectious and parasitic diseases as a cause of seizures: geographic distribution and contribution to the burden of epilepsy.” Epileptic disorders : international epilepsy journal with videotape (2022). PMID: 36219093 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [174]
Fung JST, Hwang B, Dunsmuir D et al.. “A 2-Phase Survey to Assess a Facility's Readiness for Pediatric Essential Emergency and Critical Care in Resource-Limited Settings: A Literature Review and Survey Development.” Pediatric emergency care (2022). PMID: 35981329 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [175]
Bangirana P, Bond C, Namazzi R et al.. “Cerebral Malaria and Severe Malarial Anemia, but not Other Forms of Severe Malaria, Are Associated With Long-Term Cognitive Impairment.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 41631529 ↗
L5OTHERCited in: Supportive Care and Complication Management - [176]
Torres-Fernandez D, Dalsuco J, Garcia-Mauriño C et al.. “Epidemiology and Outcomes of Pediatric Fever in a Rural District of Southern Mozambique: 17 Years of Morbidity Surveillance.” Open forum infectious diseases (2025). PMID: 41394513 ↗
L5OTHERCited in: Supportive Care and Complication Management - [177]
John Mwang'onde B. “Chlorfenapyr-pyrethroid nets for pyrethroid-resistant malaria vectors: efficacy, resistance risks, and policy implications.” Global health action (2026). PMID: 41766494 ↗
L2aSR_OBSCited in: Prevention and Screening - [178]
Tungu PK, Sudi W, Batengana B et al.. “Efficacy of long-lasting insecticidal nets before and after the selection of pyrethroid-resistant Anopheles gambiae s.l. and Anopheles funestus s.l. in northeastern Tanzania: A longitudinal meta-analysis of experimental hut trials at a single location.” Parasites & vectors (2026). PMID: 41742175 ↗
L2aSR_OBSCited in: Prevention and Screening - [179]
Firdaus MH, Ho Imran DS, Puteh SEW et al.. “Strategic resource allocation for malaria elimination in endemic settings: a systematic review of cost-effectiveness evidence.” Frontiers in public health (2025). PMID: 41737900 ↗
L2aSR_OBSCited in: Prevention and Screening - [180]
Tandel N, Thakkar M, Ahuja M et al.. “Poly(I:C) and R848 adjuvants elicit sizeable humoral immunity to liver stage malaria antigens.” Frontiers in immunology (2026). PMID: 41983137 ↗
L5OTHERCited in: Prevention and Screening - [181]
Donassolo RA, Soares da Veiga GT, Nisimura LM et al.. “Naturally acquired antibodies to Plasmodium vivax Pv_LISP-2, a potential liver stage vaccine antigen.” Frontiers in immunology (2026). PMID: 41972120 ↗
L5OTHERCited in: Prevention and Screening - [182]
Su JS, Stover J, Pretorius C et al.. “The benefits of investments to combat HIV, tuberculosis, and malaria for primary healthcare from 2000 to 2023: An economic modeling analysis.” PLoS medicine (2026). PMID: 41950262 ↗
L5OTHERCited in: Prevention and Screening - [183]
Guido G, Totaro V, Lochoro P et al.. “Household and community-based approaches to malaria and cholera prevention: A narrative review with case studies from Uganda and Mozambique.” PLoS neglected tropical diseases (2026). PMID: 41941455 ↗
L5REVIEW_NARRATIVECited in: Prevention and Screening - [184]
Zhu Y, Wu S, Qi Y et al.. “Reinventing malaria control: hierarchical intervention strategies for African settings based on the microbiota-barrier-innate immunity axis.” Frontiers in immunology (2026). PMID: 41929484 ↗
L5REVIEW_NARRATIVECited in: Prevention and Screening - [185]
Traoré N, Zabré P, Millogo O et al.. “Assessing the role of interventions and climate on malaria mortality among children under five years of age: insights from two decades of data from the Health Demographic Surveillance System of Nouna, Burkina Faso.” Journal of global health (2026). PMID: 41926164 ↗
L5OTHERCited in: Prevention and Screening - [186]
Yahouedo AG, Merle CS, Diallo I et al.. “Climate change and malaria control in Africa: country experiences and strategic responses.” Malaria journal (2026). PMID: 41923083 ↗
L5REVIEW_NARRATIVECited in: Prevention and Screening - [187]
Diallo EM, Langlet A, Onyango LA et al.. “Healthcare providers' knowledge, perceptions and practices of malaria control strategies in the Republic of Guinea: insights from a qualitative study.” BMJ global health (2026). PMID: 41916616 ↗
L5OTHERCited in: Prevention and Screening - [188]
Diallo MA, Tine A, Sow D et al.. “Emergence of Plasmodium falciparum pfdhps A581G mutation in Southern Senegal under Seasonal Malaria Chemoprevention pressure, 2020-2023.” Communications medicine (2026). PMID: 41896338 ↗
L5OTHERCited in: Prevention and Screening - [189]
Josue Kedakse TSN, Kaba M, Baonga SF et al.. “Evaluation of the first malaria vaccine introduction: ongoing learning opportunities during the introduction into routine immunisation in Cameroon.” BMJ global health (2026). PMID: 41887666 ↗
L5OTHERCited in: Prevention and Screening - [190]
Lu S, Ding W, Huang L et al.. “The Institution-based Network on China-Africa Cooperation for Malaria Elimination: fostering a transcontinental hub for strengthening China-Africa cooperation on malaria control and elimination efforts.” Infectious diseases of poverty (2026). PMID: 41872959 ↗
L5OTHERCited in: Prevention and Screening - [191]
Mediavilla A, García X, Martínez-Vallejo P et al.. “Molecular markers of antimalarial drug resistance in pfk13, pfmdr1, pfdhfr, and pfdhps genes of Plasmodium falciparum in a rural municipality in Cubal, Benguela Province, Angola (2022-2023).” Malaria journal (2026). PMID: 41840616 ↗
L5OTHERCited in: Prevention and Screening - [192]
Audibert C, Borghini-Fuhrer I, El Gaaloul M et al.. “Improving malaria chemoprevention coverage in pregnancy: Surveying stakeholder preferences for new product profiles and community-delivery approaches across five African countries.” PLOS global public health (2026). PMID: 41824506 ↗
L5OTHERCited in: Prevention and Screening - [193]
Otoo BAF, Opoku-Mireku M, Seaneke SK et al.. “Incidence and trends of adverse drug reactions during seasonal malaria chemoprevention among children: evidence from Ghana's pharmacovigilance database, 2015-2023.” Malaria journal (2026). PMID: 41814293 ↗
L5OTHERCited in: Prevention and Screening - [194]
Ando Y, Mori K, Bradley J et al.. “Determination of the preliminary discriminating concentration of broflanilide against malaria vector mosquito Anopheles gambiae by multi-centre susceptibility testing.” Malaria journal (2026). PMID: 41803905 ↗
L5OTHERCited in: Prevention and Screening - [195]
Dolo AM, Cissoko M, Teme A et al.. “Extreme rainfall, flooding and malaria in the Sahara: outbreak analysis in Kidal, Mali 2024.” Malaria journal (2026). PMID: 41792755 ↗
L5OTHERCited in: Prevention and Screening - [196]
Lake MW, Asemahagn MA, Gelaye KA et al.. “Climate, environmental, and programmatic correlates of malaria resurgence in Amhara, Ethiopia (2018-2024): a Bayesian spatiotemporal analysis.” Malaria journal (2026). PMID: 41782025 ↗
L5OTHERCited in: Prevention and Screening - [197]
Begashaw DT, Alemayehu MA, Animut Y et al.. “Utilization and associated factors of long-lasting insecticide-treated nets among households in Gondar Zuria district, Northwest Ethiopia: a mixed methods study, 2025.” Malaria journal (2026). PMID: 41781949 ↗
L5OTHERCited in: Prevention and Screening - [198]
Rodrigues R, Dhatrak A, Bal M et al.. “Design of an implementation research study for a digital omnichannel community engagement and risk communication intervention for the prevention and control of vector-borne diseases in India: the OMNIVEC-India study protocol.” Frontiers in public health (2025). PMID: 41777371 ↗
L5OTHERCited in: Prevention and Screening - [199]
Laurenson AJ, Pierce BG, Takala-Harrison S et al.. “TEpiNom: A computational framework integrating population data to prioritize Plasmodium falciparum T cell epitopes.” Vaccine (2026). PMID: 41775037 ↗
L5OTHERCited in: Prevention and Screening - [200]
Atijosan A, Atijosan A, Salau AO. “Geospatial mapping of gender-sensitive malaria vulnerability and ITN usage barriers in Zamfara State, Nigeria.” Malaria journal (2026). PMID: 41772643 ↗
L5OTHERCited in: Prevention and Screening - [201]
Challenger JD, Biggs J, Skarp J et al.. “Combining statistical and dynamical modelling to guide the design of cluster randomised trials for malaria.” BMJ global health (2026). PMID: 42665358 ↗
L1bCited in: Epidemiology and Risk Factors - [202]
Ihamuotila R, Juma J, Haidara F et al.. “A single dose of azithromycin versus placebo for malaria in infants: A cluster-randomized trial.” PLOS global public health (2026). PMID: 42623398 ↗
L1bCited in: Epidemiology and Risk Factors - [203]
Owusu-Kyei K, Cussó M, Fombah AE et al.. “Causes of mortality and severe morbidity in young children in Sierra Leone: a prospective cohort study.” The Lancet. Global health (2026). PMID: 42575116 ↗
L1bCited in: Epidemiology and Risk Factors - [204]
Phiri KS, Mzembe G, Vokhiwa M et al.. “Iron or Multiple Micronutrient Powder Supplements With Malaria Chemoprevention in Rural Malawian Children: The IRMA Randomized Clinical Trial.” JAMA (2026). PMID: 42560689 ↗
L1bCited in: Epidemiology and Risk Factors - [205]
Sanz Gutierrez A, Otuko R, Xie K et al.. “Spatial exploration of the impact of cattle on risk of malarial infection using data from a cluster randomised trial.” BMJ global health (2026). PMID: 42547249 ↗
L1bCited in: Epidemiology and Risk Factors - [206]
Yaro JB, Ouedraogo A, Moreno M et al.. “Impact of directly observed treatment and extended age range of seasonal malaria chemoprevention with sulfadoxine-pyrimethamine plus amodiaquine in Burkina Faso: a three-group, open-label, cluster-randomised, controlled trial.” The Lancet. Infectious diseases (2026). PMID: 42526467 ↗
L1bCited in: Epidemiology and Risk Factors - [207]
Nicolas P, Mundaca H, Brazeal A et al.. “Risk of adverse pregnancy outcomes following inadvertent exposure to ivermectin during the periconception period: findings from two cluster-randomized trials in Mozambique and Kenya.” EClinicalMedicine (2026). PMID: 42518939 ↗
L1bCited in: Epidemiology and Risk Factors - [208]
Milburn J, Williamson A, Baljekar S et al.. “Outpatient Management of Imported Nonsevere Falciparum Malaria in Adults in the United Kingdom: A Multisite Evaluation of Clinical Safety and Costing Analysis.” Open forum infectious diseases (2026). PMID: 42621555 ↗
L4Cited in: Epidemiology and Risk Factors - [209]
Ulusan Bağcı Ö, Elhan AH, Akarsu GA. “Efficacy of artemisinin derivatives and kelch13 mutations in Plasmodium falciparum: a systematic review and meta-analysis.” Transactions of the Royal Society of Tropical Medicine and Hygiene (2026). PMID: 42529832 ↗
L2aCited in: Epidemiology and Risk Factors - [210]
Boafo EA, Amponsah RD, Atiase Y et al.. “Pre-Eclampsia Among Pregnant Women in Ghana: A Systematic Review & Meta-Analysis of the Current Prevalence, Risk Factors, and Perinatal Outcomes.” Health science reports (2026). PMID: 42518548 ↗
L2aCited in: Epidemiology and Risk Factors - [211]
Vera-Ponce VJ, Ballena-Caicedo J, Delgado-Toro HE et al.. “Malaria Coinfections Worldwide: An Umbrella Systematic Review of Prevalence and Epidemiological Patterns.” Tropical medicine and infectious disease (2026). PMID: 42506776 ↗
L2aCited in: Epidemiology and Risk Factors - [212]
Alkoshi S, Mohsen A. “Post-flood communicable disease surveillance following the 2023 dam collapse in Eastern Libya.” PLOS global public health (2026). PMID: 42623422 ↗
L3bCited in: Epidemiology and Risk Factors - [213]
Scott R, Olsen CH, Mancuso JD et al.. “Multimorbidity Trajectories and Hospitalization Risk Among People With Human Immunodeficiency Virus in Sub-Saharan Africa: A Longitudinal Analysis From the African Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 42550040 ↗
L3bCited in: Epidemiology and Risk Factors - [214]
Elsiwi B, Eskenazi B, Bornman R et al.. “Maternal exposure to pyrethroid insecticides during pregnancy and repeated measures of infection symptoms among early school-aged children in the Venda Health Examination of Mothers, Babies and their Environment (VHEMBE).” Chemosphere (2026). PMID: 42501461 ↗
L3bCited in: Epidemiology and Risk Factors - [215]
Chinawa JM, Chukwu BF, Okafor HU. “Echocardiographic assessment of cardiac function in children with severe malaria attending two tertiary hospitals in southeast Nigeria.” European journal of pediatrics (2026). PMID: 42498795 ↗
L3bCited in: Epidemiology and Risk Factors - [216]
Fornah L, Osborne A, Shimbre MS et al.. “Incidence and predictors of loss to follow-up after ART initiation at public health facilities in Sierra Leone (2020-2024): a retrospective cohort study.” BMJ open (2026). PMID: 42498473 ↗
L3bCited in: Epidemiology and Risk Factors - [217]
Mwebesa E, Agbi DM, Agasa LO et al.. “Estimating Causal Effects of Malaria Infection on Anaemia Among Children Under Five Years in Uganda: Evidence From a Cross-Sectional Malaria Indicator Survey.” Health science reports (2026). PMID: 42564307 ↗
L2bCited in: Epidemiology and Risk Factors - [218]
Otsyula N, Polavarapu NK, Syntosi A et al.. “Understanding barriers to effective malaria diagnosis and treatment: A mixed-methods study in Uganda, Nigeria, and Ivory Coast.” PLOS global public health (2026). PMID: 42607037 ↗
L4Cited in: Epidemiology and Risk Factors - [219]
Bandzuh JT, Ernst KC, Uejio CK et al.. “Knowledge, attitudes, and practices related to spatial repellent for mosquito control and malaria risk perception in East Sumba, Indonesia.” PLOS global public health (2026). PMID: 42566481 ↗
L3bCited in: Epidemiology and Risk Factors - [220]
Yewodiaw TK, Endalew HL, Getnet M et al.. “Prevalence, spatial distribution, and determinants of anemia among under-five children in the Democratic Republic of Congo: evidence from the 2023-24 DHS.” International journal of health geographics (2026). PMID: 42538531 ↗
L3bCited in: Epidemiology and Risk Factors - [221]
Mshamu S, Mukaka M, Sanga C et al.. “A sustainable house design to improve child health in rural Africa: a cluster-randomized controlled trial.” Nature medicine (2026). PMID: 42014505 ↗
L1bCited in: History and Physical Examination - [222]
Hiruy HN, Liu E, Worku A et al.. “Associations of Malaria, Diarrhea, and Respiratory Infections with Growth Velocity of Children in Tanzania.” The American journal of tropical medicine and hygiene (2026). PMID: 41946349 ↗
L1bCited in: History and Physical Examination - [223]
Tear AA, Fauziah N, Riswari SF et al.. “Prognostic factors in malaria patients with acute kidney injury: a systematic review and meta analysis.” Renal failure (2026). PMID: 42185742 ↗
L2aCited in: History and Physical Examination - [224]
Ofosu W, Odoom A, Anim-Baidoo I et al.. “Infectious Agents of Non-Malarial Febrile Illnesses in 20 African Countries, 2019-2024: A Systematic Review and Meta-Analysis.” Tropical medicine & international health : TM & IH (2026). PMID: 41983654 ↗
L2aCited in: History and Physical Examination - [225]
Doumbia L, Thirion L, Klitting R et al.. “Study of patients with acute undifferentiated fever identifies dengue as a growing threat to public health in Mali.” PLoS neglected tropical diseases (2026). PMID: 42418522 ↗
L4Cited in: History and Physical Examination - [226]
Hamer DH, Loreau JM, Huits R et al.. “Frequency and persistence of post-acute symptoms after chikungunya, dengue, Zika and malaria in travellers: a prospective multi-centre study.” Journal of travel medicine (2026). PMID: 42149962 ↗
L3bCited in: History and Physical Examination - [227]
Merci M, Dieudonné KO, Nina G et al.. “Rickettsia typhi seroprevalence among patients with unexplained acute fever at the Sourô Sanou University Hospital Center (SSUHC), Burkina Faso.” BMC infectious diseases (2026). PMID: 42032490 ↗
L3bCited in: History and Physical Examination - [228]
Dieci M, Nekesa C, Kayaro NI et al.. “Guideline-concordant care and outcomes for pediatric malaria cases: descriptive evidence from pharmacy-based fever management in Kenya.” Malaria journal (2026). PMID: 41947176 ↗
L3bCited in: History and Physical Examination - [229]
Caronni S, Pieruzzi ME, Salari F et al.. “High rate of undiagnosed cases of fever among returning travelers from tropical areas tested for malaria: a single-center retrospective study.” Travel medicine and infectious disease (2026). PMID: 41812810 ↗
L3bCited in: History and Physical Examination - [230]
Kiemde F, Tahita MC, Rouamba T et al.. “C-reactive protein, white blood cell counts and sequential interpretation of PfHRP2/pLDH for antibiotic stewardship in children under 5 years of age.” BMC infectious diseases (2026). PMID: 41749173 ↗
L3bCited in: History and Physical Examination - [231]
Sabi H, Asuquo D, Attai K et al.. “Risk factors analysis of febrile diseases in LMICs: a case of southern Nigeria.” BMC infectious diseases (2026). PMID: 42045853 ↗
L4Cited in: History and Physical Examination - [232]
Gyasi WA, Boampong K, Sylverken J et al.. “Malaria and bacteremia in febrile children presenting at a teaching hospital in Kumasi, Ghana.” BMC infectious diseases (2026). PMID: 42045840 ↗
L3bCited in: History and Physical Examination - [233]
Bond C, Batte A, Afolayan F et al.. “Identification of acute kidney injury in African children hospitalized with malaria: a multinational individual participant data meta-analysis.” BMC medicine (2026). PMID: 42482088 ↗
L2aCited in: Clinical Features and Variants - [234]
Belete AM, Camara A, Yazie TS et al.. “Transplacental transfer of anti-malarial antibodies: a systematic review.” Frontiers in immunology (2026). PMID: 42404900 ↗
L2aCited in: Clinical Features and Variants - [235]
Ranjan S, Dubey M, Sharma S et al.. “Association of ABO Blood Group and Severe Plasmodium falciparum Malaria: An Updated Meta-Analysis and Trial Sequential Analysis.” Tropical medicine & international health : TM & IH (2026). PMID: 42320994 ↗
L2aCited in: Clinical Features and Variants - [236]
Mombo-Ngoma G, Adoke Y, Manego RZ et al.. “Safety, pharmacokinetics, and antimalarial efficacy of single-dose cabamiquine-pyronaridine combination therapy for the treatment of adults and adolescents with acute uncomplicated Plasmodium falciparum malaria (CAPTURE 1): a prospective, multicentre, open-label, phase 2a study.” The Lancet. Infectious diseases (2026). PMID: 42462745 ↗
L4Cited in: Clinical Features and Variants - [237]
Okullo AE, Idro R, van Hensbroek MB et al.. “Neurologic sequelae of cerebral malaria and other forms of severe malaria in children.” Pediatric research (2026). PMID: 42401781 ↗
L2bCited in: Clinical Features and Variants - [238]
Shiba M, Liu Z, Higo S et al.. “Clinical and Experimental Insights into Hydroxychloroquine-Associated Electrical Abnormalities and Cardiomyopathy.” European heart journal. Cardiovascular pharmacotherapy (2026). PMID: 42637670 ↗
L4Cited in: Clinical Features and Variants - [239]
Monkoti Manzi MG, Nsibu C, Bodi J et al.. “Severe malaria-bacterial sepsis co-infection among critically ill children admitted to pediatric emergency departments in Kinshasa.” World journal of clinical pediatrics (2026). PMID: 42626138 ↗
L3bCited in: Clinical Features and Variants - [240]
Charoensakulchai S, Tangpukdee N, Wilairatana P et al.. “Delayed diagnosis of Plasmodium vivax malaria and associated factors among Thai patients and patients from neighboring countries at the Hospital for Tropical Diseases, Bangkok, Thailand.” Infection (2026). PMID: 42606671 ↗
L3bCited in: Clinical Features and Variants - [241]
Vidal-Cardenas E, De Freitas-Vidal CI, Soto-Calle V et al.. “Health-care provider compliance with a revised Plasmodium vivax radical cure algorithm incorporating tafenoquine and quantitative G6PD testing in the Peruvian Amazon: a prospective observational study.” Lancet regional health. Americas (2026). PMID: 42500357 ↗
L4Cited in: Clinical Features and Variants - [242]
Sha T, Cao Y, Liu K et al.. “Healthcare utilization patterns and diagnostic delays among international migrant workers with imported malaria in China: a retrospective cohort analysis.” Malaria journal (2026). PMID: 42399742 ↗
L3bCited in: Clinical Features and Variants - [243]
Moutombi-Ditombi BC, Lembet Mikolo AM, Ndong Ngomo JM et al.. “Clinical profiles and predictors of intensive care unit transfer among children hospitalized with severe Plasmodium falciparum malaria in a tertiary care hospital in Libreville, Gabon: a retrospective study.” BMC infectious diseases (2026). PMID: 42265612 ↗
L3bCited in: Clinical Features and Variants - [244]
Patel AA, Nishat S, Joshi RB et al.. “Following Severe Pediatric Malaria, Epilepsy Screening Is Needed Even Among Children Without Coma: Findings From a Prospective Cohort Study.” Journal of central nervous system disease (2026). PMID: 42436689 ↗
L2bCited in: Clinical Features and Variants - [245]
Zhao W, Wang J, Du XY et al.. “Dihydroartemisinin-stachyose conjugate (sDHA) improves the oral bioavailability of dihydroartemisinin and antiemphalitic malaria effects.” Nanomedicine : nanotechnology, biology, and medicine (2026). PMID: 42331046 ↗
L3bCited in: Clinical Features and Variants - [246]
Luzolo Khote F, Raposo M, Maseko T et al.. “Prevalence of antimalarial drug resistance markers and factors associated with Plasmodium falciparum infection in asymptomatic children prior to rectal artesunate implementation in Kapolowe Health District, Democratic Republic of the Congo.” Malaria journal (2026). PMID: 42374417 ↗
L3bCited in: Clinical Features and Variants - [247]
Camara S, Buck A, Burrell M et al.. “Immunomodulation Therapy to Treat Severe Malaria With Multiple Organ Failure.” Critical care explorations (2026). PMID: 42644869 ↗
L4Cited in: Clinical Features and Variants - [248]
Cugliari M, Piacentini F, Montorfani SMMA et al.. “Acute acalculous cholecystitis and blackwater fever with acute kidney injury in children with malaria: case series and literature review.” Malaria journal (2026). PMID: 42316152 ↗
L4Cited in: Clinical Features and Variants - [249]
Cassol C, Rossetti B, Cosma C et al.. “Cryptic severe Plasmodium falciparum malaria in Maremma (Tuscany, Italy), 2024: a case report from a historically receptive area.” Travel medicine and infectious disease (2026). PMID: 42263924 ↗
L4Cited in: Clinical Features and Variants - [250]
Okullo CO, Nakaziba R. “Community Knowledge, Self-Reported Prevalence, and Management of Epilepsy in Lira District: A Descriptive Cross-Sectional Study.” Neuropsychiatric disease and treatment (2026). PMID: 42444840 ↗
L3bCited in: Clinical Features and Variants - [251]
Accrombessi M, Assongba L, Khairallah C et al.. “Delivery strategies for malaria chemoprevention in the post-discharge management of children hospitalised with severe anaemia or severe malaria: protocol for a cluster randomised controlled implementation trial in Benin.” BMJ open (2026). PMID: 42665339 ↗
L5Cited in: Clinical Features and Variants - [252]
Basnyat B, Adhikari S, Shrestha P et al.. “Azithromycin with or without cefixime for suspected or culture-confirmed uncomplicated typhoid fever in Nepal, Bangladesh, and Pakistan (ACT-South Asia): a double-blind, parallel-group, randomised, placebo-controlled, phase 4 trial.” The Lancet. Infectious diseases (2026). PMID: 42624818 ↗
L1bCited in: Diagnosis and Workup - [253]
Ramalan M, Rabiu A, Jibril M et al.. “Optimizing intermittent preventive treatment for malaria in pregnancy: protocol for phase IV randomized controlled trial of sulphadoxine-pyrimethamine, dihydroartemisinin-piperaquine, and combination therapy in Northern Nigeria.” BMC pregnancy and childbirth (2026). PMID: 42432528 ↗
L1bCited in: Diagnosis and Workup - [254]
. “The effect of mefloquine dose on outcome of uncomplicated falciparum malaria treated with artesunate-mefloquine: a WWARN systematic review and individual patient data meta-analysis.” Malaria journal (2026). PMID: 42638106 ↗
L2aCited in: Diagnosis and Workup - [255]
McHenry MS, Ayodo G, Marete I et al.. “Association of asymptomatic Plasmodium falciparum infections and its treatment with short-term cognitive performance in school-aged children: A prospective cohort study in western Kenya.” The Journal of infection (2026). PMID: 42617751 ↗
L2bCited in: Diagnosis and Workup - [256]
Segala FV, Ictho J, L'episcopia M et al.. “Effect of sulphadoxine-pyrimethamine resistance on birthweight and parasite persistence among women receiving intermittent preventive treatment for malaria in pregnancy in Northern Uganda: a directed acyclic graph-guided analysis.” Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (2026). PMID: 42595091 ↗
L2bCited in: Diagnosis and Workup - [257]
Mortazavi SE, Lugaajju A, Tijani MK et al.. “Malaria exposure history shapes PD-1 expression across human B-cell subsets during acute Plasmodium falciparum infection.” BMC microbiology (2026). PMID: 42458286 ↗
L3bCited in: Diagnosis and Workup - [258]
Abali IE, Adeoye IA, Afolabi RF et al.. “Lassa fever in the shadow of pregnancy - a case-control study of clinical presentation, risk factors and outcomes in Southern Nigeria.” BMC pregnancy and childbirth (2026). PMID: 42410380 ↗
L3bCited in: Diagnosis and Workup - [259]
Baina MT, Mouanga AM, Vouvoungui C et al.. “Low practical knowledge but high willingness to use malaria rapid diagnostic tests among healthcare workers in the Republic of Congo.” BMC public health (2026). PMID: 42576208 ↗
L3bCited in: Diagnosis and Workup - [260]
Sidi Omar SFN, Ngui R, Jiee SF et al.. “Low prevalence of sub-microscopic malaria among rural communities of an endemic area in Kapit Division, Malaysian Borneo.” Malaria journal (2026). PMID: 42437921 ↗
L3bCited in: Diagnosis and Workup - [261]
Srivastava B, Anvikar A, Anvikar D et al.. “Prospective Assessment of the Performance of a Combi-Rapid Diagnostic Test to Accurately Diagnose Malaria and Detect C-Reactive Protein in Selected Settings in India.” The American journal of tropical medicine and hygiene (2026). PMID: 42480513 ↗
L3bCited in: Diagnosis and Workup - [262]
Wazodan AM, Lamine MM, Alkassoum I et al.. “[Impact of introducing a fifth monthly cycle of seasonal malaria chemoprevention among children aged 3 to 59 months: a quasi-experimental difference-in-differences study in the Zinder Region, Niger].” The Pan African medical journal (2026). PMID: 42662648 ↗
L2bCited in: Diagnosis and Workup - [263]
Tandina F, Doumbo SN, Djimdé M et al.. “Malaria Vectors' Diversity and Seasonality in Sustaining Disease Transmission in an Endemic Area of Faladie, Mali.” Tropical medicine and infectious disease (2026). PMID: 42646793 ↗
L3bCited in: Diagnosis and Workup - [264]
Mensah BT, Otu H, Armah DNO et al.. “Submicroscopic Plasmodium falciparum Carriage and Molecular Markers of Antimalarial Drug Resistance Among Outpatients Attending Korle Bu Teaching Hospital, Ghana.” Tropical medicine and infectious disease (2026). PMID: 42506760 ↗
L3bCited in: Diagnosis and Workup - [265]
Konja BA, Agyapong NAF, Ocran EK et al.. “Targeting childhood malaria: insights from multi-country DHS data in Sub-Saharan Africa.” BMC pediatrics (2026). PMID: 42481992 ↗
L3bCited in: Diagnosis and Workup - [266]
Bekolo CE, Zekeng GAS, Onambele P et al.. “Accessibility, safety, and early effect of the malaria vaccine in routine immunisation practice among children under 36 months in the Soa Health District, Cameroon.” Tropical medicine and health (2026). PMID: 42421129 ↗
L3bCited in: Diagnosis and Workup - [267]
Mandai SS, Kisambale AJ, Petro DA et al.. “Mapping of the country-wide prevalence of non-malarial febrile illnesses in areas with varying malaria transmission intensities in Mainland Tanzania.” Gates open research (2026). PMID: 42404095 ↗
L3bCited in: Diagnosis and Workup - [268]
Chin JY, Rénia L, Lee WC. “IGFBP7 induces phenotypic shift from platelet-mediated autoagglutination to rosetting of Plasmodium knowlesi-infected erythrocytes.” Virulence (2026). PMID: 42661346 ↗
L5Cited in: Diagnosis and Workup - [269]
O'Brien NF, Postels DG, Chimalizeni Y et al.. “Adjunctive Mechanical Ventilation or Intravenous Hypertonic Saline in Malawian Children with Cerebral Malaria and Highly Increased Brain Volume: A Randomized, Phase 3 Clinical Trial.” Neurocritical care (2026). PMID: 42230477 ↗
L1bCited in: Supportive Care and Complication Management - [270]
Ochanda PN, Aakvik A, Bangirana P et al.. “Severe malarial anaemia in childhood is associated with decreased long-term household wealth.” BMC public health (2025). PMID: 41291612 ↗
L2bCited in: Supportive Care and Complication Management - [271]
Balerdi-Sarasola L, Muñoz J, Fleitas P et al.. “Not all severe malaria cases are severe: Is it time to redefine severity criteria for malaria in non-endemic regions?” Travel medicine and infectious disease (2024). PMID: 39002737 ↗
L4Cited in: Supportive Care and Complication Management - [272]
Ma G, Hou C, Li Y et al.. “Global burden of childhood Burkitt lymphoma (1990-2021): epidemiological trends, regional disparities, and projections for 2035 from the Global Burden of Disease Study.” Frontiers in medicine (2025). PMID: 41070076 ↗
L3bCited in: Supportive Care and Complication Management - [273]
Doka Hélène KS, Ignatius E, Berinyuy M et al.. “Nonsurgical Neurological Emergencies in Children: A Cross-Sectional Study of Prevalence, Diagnosis, and Management.” Pediatric neurology (2025). PMID: 40609287 ↗
L3bCited in: Supportive Care and Complication Management - [274]
Huang M, Jia X, Wang X et al.. “Severe Plasmodium falciparum malaria with marked ADAMTS13 reduction and secondary microangiopathic features: A case report.” Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy (2026). PMID: 42636958 ↗
L3bCited in: Supportive Care and Complication Management - [275]
Moutombi Ditombi BC, Manomba Boulingui C, Mayandza C et al.. “Parasitic and fungal central nervous system infections in hospitalised adults living with HIV in Libreville, Gabon: clinical profiles to inform syndromic triage in resource limited settings.” AIDS research and therapy (2026). PMID: 41546100 ↗
L3bCited in: Supportive Care and Complication Management - [276]
Whitworth HS, Beshir KB, Baisley KJ et al.. “Effect of malaria parasitaemia on antibody responses to single-dose and two-dose HPV vaccination: results from the DoRIS dose-reduction immunogenicity trial in Tanzanian girls.” Vaccine (2026). PMID: 42378813 ↗
L1bCited in: Prevention and Screening - [277]
LaVerriere E, Kelley K, Dicko A et al.. “Genotypic analysis of Plasmodium falciparum malaria parasites in a clinical trial of RTS,S vaccination in combination with seasonal malaria chemoprevention.” Malaria journal (2026). PMID: 42393745 ↗
L2bCited in: Prevention and Screening - [278]
Ndung'u L, Muriithi B, Gitahi S et al.. “Regional Patterns and Temporal Trends of Pfdhfr and Pfdhps Markers of Antifolate Resistance in Plasmodium falciparum in East and West Africa, 2010-2025: A Systematic Review.” Acta tropica (2026). PMID: 42437651 ↗
L2aCited in: Prevention and Screening - [279]
Simanjuntak AMT, Wijayanto FPS, Nugraha RTH et al.. “Efficacy of dihydroartemisinin-piperaquine to prevent malaria and complication-related malaria during pregnancy compared to sulfadoxine-pyrimethamine: a systematic review, meta-analysis, and meta-regression.” Epidemiology and infection (2026). PMID: 42415480 ↗
L2aCited in: Prevention and Screening - [280]
Safari MS, Makori TO, Gicheru ET et al.. “A natural experiment in Kenya reveals durable immunosuppressive effects of early childhood malaria: a longitudinal cohort study.” eLife (2026). PMID: 42444449 ↗
L3bCited in: Prevention and Screening - [281]
Namubiru C, Mahmoudou S, Djida Y et al.. “Linking health literacy to malaria prevention and treatment behaviours: evidence from a community-based study in Gabon.” BMC health services research (2026). PMID: 42642735 ↗
L3bCited in: Prevention and Screening - [282]
Ewinetu MK, Mekonen Belay B, Abere Y. “Malaria prevention practice and associated factors among residents in Fogera district, Ethiopia, during the armed conflict between Amhara Fano forces and the federal government, 2025.” Malaria journal (2026). PMID: 42482058 ↗
L3bCited in: Prevention and Screening - [283]
Hicks JT, Munsey A, Mousa A et al.. “Disentangling patterns of community malaria transmission and burden using malaria prevalence among pregnant women attending antenatal care: a modelling study.” The Lancet. Microbe (2026). PMID: 42456694 ↗
L3bCited in: Prevention and Screening - [284]
Andriamasy EH, Razafimanantsoa H, Tiaray Harison M et al.. “Community health worker involvement across domains and national infectious disease programmes in rural Madagascar: evidence of fragmentation and determinants of engagement.” BMJ global health (2026). PMID: 42419867 ↗
L3bCited in: Prevention and Screening - [285]
Lequechane JD, Lopes LF, Gonçalves L et al.. “Field evaluation of 3-(N-acetyl-n-butyl) aminopropionic acid ethyl ester - IR3535 as a spatial repellent to control malaria: A Randomised, Before-After-Control-Intervention trial.” PloS one (2026). PMID: 42531228 ↗
L1bCited in: Prevention and Screening - [286]
Zhang T, Huang S, Ibinaiye T et al.. “Understanding the Dimensions of Caregiver-Perceived Seasonal Malaria Chemoprevention Delivery Quality in Nigeria: A Structural Equation Modeling Analysis of Door-to-Door Seasonal Malaria Chemoprevention.” The American journal of tropical medicine and hygiene (2026). PMID: 42641592 ↗
L3bCited in: Prevention and Screening - [287]
Glover AC, Koenker H, Niang EHA et al.. “Heterogeneity of use, access, and retention of insecticide-treated nets: Implications for subnational tailoring to maximise malaria control.” eLife (2026). PMID: 42623257 ↗
L5Cited in: Prevention and Screening - [288]
Sullivan DJ. “Monoclonal antibody CIS43LS sets the bar for long-acting malaria protection.” The Journal of clinical investigation (2026). PMID: 42606125 ↗
L5Cited in: Prevention and Screening - [289]
Mim SR, Xavier LC, Azeredo FJ et al.. “Quantitative and Clinical Pharmacology Perspectives on Next-Generation Malaria Prevention Using Vaccines and Long-Acting Monoclonal Antibodies.” Clinical and translational science (2026). PMID: 42587382 ↗
L5Cited in: Prevention and Screening - [290]
Sha T, Liao Z, Yuan T et al.. “Imported mosquito-borne infectious diseases in travellers and migrants: Global patterns, clinical overlap, and prevention gaps-an umbrella review of 21 systematic reviews.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 42810509 ↗
L2aCited in: Clinical Features and Variants - [291]
Rehman AU, Nnaemeka V, Nasir MH et al.. “Efficacy and Response of R21/Matrix-M in Malaria Vaccine: A Systematic Review and Meta-Analysis of Clinical Trials.” Vaccines (2026). PMID: 42797644 ↗
L2aCited in: Clinical Features and Variants - [292]
Ortiz-Fernández M, Balerdi-Sarasola L, Ciminelli F et al.. “Community-acquired coinfections in adults with severe imported malaria: a systematic review and meta-analysis.” Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (2026). PMID: 42754092 ↗
L2aCited in: Clinical Features and Variants - [293]
Mellencamp KA, Namazzi R, Batte A et al.. “Long-term mortality and risk of chronic kidney disease in children following severe malaria complicated by acute kidney injury: a prospective observational study.” The Lancet. Global health (2026). PMID: 42575118 ↗
L2bCited in: Clinical Features and Variants - [294]
Niu B, Wang R, Tian H et al.. “Clinical contribution of mNGS in the diagnosis and management of imported falciparum malaria in a malaria-free region: a five-case series from northern China.” Frontiers in cellular and infection microbiology (2026). PMID: 42851315 ↗
L4Cited in: Clinical Features and Variants - [295]
Peng K, Gong W, Dong X et al.. “Epidemiological and clinical characteristics of imported malaria patients admitted to a specialized hospital: a retrospective study (2021- June 2026).” Frontiers in cellular and infection microbiology (2026). PMID: 42835030 ↗
L4Cited in: Clinical Features and Variants - [296]
Negash AA, Woudineh MT, Mohammed KH et al.. “Emerging predominance of Plasmodium vivax and its contribution to severe malaria in Central Ethiopia: a mixed retrospective-prospective study from two tertiary hospitals.” BMC infectious diseases (2026). PMID: 42806321 ↗
L3bCited in: Clinical Features and Variants - [297]
Pikor D, Duda J, Ciechanowski M et al.. “Clinical Spectrum and Admission Correlates of Complicated Imported Malaria in Polish Travellers: An 11-Year Retrospective Analysis with Geographic Mapping of Travel Destinations.” Journal of clinical medicine (2026). PMID: 42796040 ↗
L3bCited in: Clinical Features and Variants - [298]
Oduro D, Konadu EA, Obiri D et al.. “Longitudinal dynamics of angiopoietin-1, angiopoietin-2 and soluble thrombomodulin during recovery from paediatric cerebral malaria in Ghana.” Acta tropica (2026). PMID: 42838407 ↗
L2bCited in: Clinical Features and Variants - [299]
Bekolo CE, Ngouenko N, Dipepa Nwall ELN et al.. “Assessing the impact of routine malaria vaccination on total disease burden in Cameroon: a nationwide difference‑in‑differences analysis using health district surveillance data (2023-2025).” Tropical diseases, travel medicine and vaccines (2026). PMID: 42823750 ↗
L2bCited in: Clinical Features and Variants - [300]
Kamphuis AEM, Salvadori N, Mujuru HA et al.. “Expediting a UNIVERSAL first-line regimen of a dolutegravir-emtricitabine-tenofovir alafenamide fixed-dose ratio for children living with HIV older than 4 weeks: a 24-week, open-label, single-arm, phase 1-2, pharmacokinetic, safety, and antiviral activity trial.” The lancet. HIV (2026). PMID: 42705257 ↗
L4Cited in: Clinical Features and Variants - [301]
Seo JW, Kim DY, Yun NR et al.. “Postdeployment Plasmodium Infections among South Korean Soldiers Receiving Mefloquine Chemoprophylaxis in South Sudan.” The American journal of tropical medicine and hygiene (2026). PMID: 42810327 ↗
L3bCited in: Clinical Features and Variants